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Worldwide, there are an estimated 33.4 million people infected with Human 
Immunodeficiency Virus (HIV-1), of which 67% live in sub-Saharan Africa (UNAIDS, 
2009). Even though many drugs have been developed which are effective at reducing 
the viral load to undetectable levels (UNAIDS, 2009), because of the integrative nature 
of the viral genome and its ability to evade elimination in nonreplicating cells, the 
ultimate solution for long-term control of HIV infection would be to have an effective 
prophylactic vaccine. Of the many vaccine trials which have taken place, the most 
promising results have been obtained from the recent phase 3 clinical trial which tested 
the ability of a dual protein and Canarypox virus recombinant to protect humans against 
HIV-1 infections (Reks-Ngarm et al., 2009). Because poxviruses are being developed as 
vaccine vectors against a number of diseases, it is important to continue the search for 
novel poxvirus vectors, in particular, those that do not cross-neutralize one another. 
 
This thesis describes the preliminary work performed on the development of 
Penguinpox virus (PEPV) as a vaccine vector. No cells are known to be permissive for 
the growth of PEPV; hence this virus was grown and titrated on chorioallantoic 
membranes (CAMs) of 10-12 day old chick embryos. Growth curve analysis confirmed 
that rabbit kidney fibroblast cells (RK-13) are not permissive for PEPV and also that 
PEPV does not adapt to growth in these cells upon multiple passage. This meant that 
RK-13 cells could potentially be used for the selection of recombinant PEPV which has 
the Vaccinia virus (VACV) K1L host range gene recombinantly integrated into its 
genome. The K1L gene has been used to rescue growth of MVA in RK-13 cells and so 
used as a selective marker gene in the construction of recombinant virus (Staibaetaal., 
2000). The aim of this project was to establish whether the K1L gene could be used as a 
11 
selection marker for the construction of recombinant PEPV. 
 
In order to make a recombinant poxvirus it is necessary to construct a transfer vector, 
which is used to transfect poxvirus-infected cells, and then to isolate the recombinant 
virus from these cells. After a series of cloning procedures a transfer vector was 
constructed. It contained the selective host range gene K1L, the marker gene GUS, 
direct repeat sequences flanking these two genes, a unique Sma I restriction enzyme site 
outside of the direct repeats and, flanking this cassette, the two ends of the PEPV 
thymidine kinase (TK) gene. This transfer vector was shown to rescue both early and 
late gene expression in RK-13 cells. However, no recombinant PEPV could be 
recovered. 
 
This is the first attempt to rescue PEPV growth in a non-permissive cell line with a VV 
host range gene. This work provides a foundation for future development of PEPV into 
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1.1.1 Classification and Phylogeny 
 
The Poxviridae is divided into two subfamilies which are highly divergent: the 
Entomopoxvirinae and the Chordopoxvirinae, which infect insects and vertebrates 
respectively (Gubser et al., 2004). The Entomopoxvirinae subfamily is divided into 3 
genera (a, b and c) while the Chordopoxvirinae, the focus of this review, are divided 
into 8 genera, (Avipoxvirus, Molluscipoxvirus, Orthopoxvirus, Capripoxvirus, 
Suipoxvirus, Leporipoxvirus, Yatapoxvirus and Parapoxvirus) (Babkin et al., 2005).  
 
The genome sequence of at least one member of each Chordopoxvirus genus is 
available in the genbank for analysis. Analysis of sequenced Chordopoxvirus genomes 
was conducted based on comparison of the sizes of these genomes, the number of 
unique genes, gene arrangement and phylogenetic analysis of the amino acid sequences 
of 17 conserved proteins among Chordopoxviruses (Gubser et al., 2004; Babkin et al., 
2005). This analysis showed Avipoxviruses to be the most divergent amongst the 
Chordopoxvirus genera followed by Molluscipoxvirus. Avipoxvirus is the only 
Chordopoxvirus genus which infects avian species whereas Molluscipoxvirus is a strict 
human pathogen. Both of these viruses have evolved unique immunomodulatory 
proteins to evade or counteract their species specific (human and avian species) immune 
response. The remainder of the Chordopoxvirus sub-family can be categorised into two 
clusters. The Leporipoxvirus, Yatapoxvirus, Capripoxvirus, Suipoxvirus and possibly 
Parapoxvirus genera were grouped together due to the relatively small size of their 
genomes (range from ~120kb to ~160kb) and the few unique genes found in the central 
conserved regions of their genomes. Members of the other group, Orthopoxvirus, were 
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found to possess relatively larger genomes (larger than 160kb) and to have unique genes 
present at the N-terminal region of the genome (Gubser et al., 2004). However, it has 
also been suggested that Parapoxvirus is more closely related to Molluscipoxvirus as 
both genera possess higher GC content (64 ~ 64.5%) compared to the rest of the 
Chordopoxviruses (GC contents of 25% ~ 43.6%). It was suggested that Avipoxviruses 
diverged from the mammalian poxviruses which possess low GC contents. However, 
due to the progressive adaptation of the Avipoxvirus genus to avian species, it has 
become highly diverged from the rest of the mammalian Chordopoxviruses  
(Babkin et al., 2005). 
 
1.1.2 Structure of Poxvirus 
 
1.1.2.1 Genome Structure 
 
Poxviruses are large double-stranded DNA viruses, with genomes ranging from 130 
to 300kb (Moss et al., 2007). Comparisons of sequenced poxvirus genomes showed 
there are 90 genes conserved in all Chordopoxviruses and 49 genes in all poxviruses. 
These conserved genes are required for transcription, translation, DNA replication, 
repair and viral structural components (Gubser et al., 2004). Conserved genes are 
generally located in the central region of the genome with gene conservation 
decreasing towards the termini (Afonso et al., 2000). The non-conserved genes, many 
of which are not essential for replication in cultured cells, are involved in host range 
and pathogenicity. At the ends of the poxvirus genome, the two strands of DNA are 
covalently-linked by terminal hair-pin loop structure (Baroudy et al., 1982). Inverted 
terminal repeat sequences (ITR) are found adjacent to the hair-pin loop structures. 
The lengths of these sequences vary amongst different poxviruses, however a highly  
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conserved concatemer resolution motif is found within the ITR as this motif is 
essential for DNA replication of poxviruses (Moss, 2007). 
 
1.1.2.2 Virion Structure 
 
Figure 1.1 shows the structure a typical poxvirus virion. Poxviruses are characterised 
by a complex, enveloped, brick-shaped virion, but can also assume a pleomorphic 
shape. The brick-shaped virion is generally ~260 nm by 220-450 nm while the 
pleomorphic virion is 160-190 nm by 250-330 nm. The core can display itself in a 
tubular unit, a globular unit or as spiral filaments (Condit et al., 2006). Virions may 
possess one or two lateral bodies accompanying the core, nested between the core 
membrane and the surface membrane. Generally Poxviruses are found in two distinct, 
infectious virus particle types, the intracellular mature virus (IMV, with a single outer 
membrane) and the extracellular enveloped virus (EEV, with a double outer 
membrane) with both particles capable of initiating the infectious cycle. These two 
virion forms differ in their surface glycoproteins and in the number of membranes 
that enclose the virion. However, there are two other forms of virion present in virus 
infected cells. Once IMV particles are produced following viral replication, they 
migrate via microtubule mediated trafficking and are wrapped with Golgi-derived 
membranes to form intracellular enveloped virus (IEV). The IEV sheds one of its 
outer membranes as it fuses with the cell membrane, forming cell-associated 
enveloped virus (CEV). CEV is either propelled toward neighbouring cells 
(McFadden, 2005) or released directly as free EEV particles. In general, CEV and 
EEV forms are particularly important for cell-cell spread whereas IMV is 





Figure 1.1. Diagram showing the virion structure of a typical poxvirus 
(http://expasy.org/viralzone/all_by_species/174.html). 
 
1.1.3 Virus Entry, Replication, Transcription and Morphogenesis 
 
Virus replication involves several stages. Poxviruses are efficient at binding and 
entering mammalian cells, regardless of whether the cell is nonpermissive or permissive. 
Binding of the virus to the cell surface and subsequent fusion of the virus and the cell 
membranes is well studied, however, the specific host receptors involved in poxvirus 
infection and the fusion event between the virion and the host cell membrane are still 
poorly understood. To date, it has been shown that several virion proteins are crucial for 
binding of the virion to the cell surface (McFadden, 2005). Poxvirus proteins A27, H3, 
D8 and A26 were found to interact with host cell surface proteins (Chiu et al., 2007) 
such as the ubiquitously expressed Glycosaminoglycans (GAG), heparin sulfate 
proteoglycan (HSPG), chondroitin sulfate proteoglycan (CSPG) and extracellular matrix 
protein laminin. However, none of these viral-cell protein interactions alone are 
essential for virus attachment to the cells, therefore virus may enter the cells through 
alternative mechanisms (Chiu et al., 2007).  
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For IMV, attachment of the virus is facilitated by the virus transmembrane, which is 
made up of several virus proteins and host cell surface protein. Once the virus binds to 
the host cell surface receptor, plasma membrane fusion occurs, releasing the viral core 
into the host cell cytoplasm (Moss, 2007). The initial fusion event is poorly understood, 
however, several conserved viral proteins have been identified that play a role in 
facilitating viral entry. Proteins such as VACV A28, A21 have been linked to the fusion-
entry event and virions that have deletion of or mutation in these proteins are still 
capable of binding to the cell surface but unable to enter the cells (Moss, 2007). 
Because EEV has an extra membrane, the penetration mechanism is divided into two 
stages. The first stage involves removal of the outer membrane of EEV. Once EEV 
surface proteins interact with the host cell surface proteins, a serial ligand-induced, non-
fusogenic mechanism is induced, resulting in disruption of the outer membrane (Law et 
al., 2006) and release of the inner virion (IMV). The second stage involves fusion of the 
IMV with the host cell surface membrane. The released viral core is then transported via 
microtubules into the host cell cytoplasm. 
 
Recent studies have shown Vaccinia virus could enter cells through two distinct 
pathways. Vaccinia virus is capable of entering the cells through direct fusion with the 
plasma membrane at neutral pH, and recent studies have shown that VACV is capable of 
using a low-pH endosomal entry pathway. The choice of two distinct pathways may 
contribute to the ability of VACV to enter a large variety of cells (Townsley et al., 2006). 
Initially, the WR strain of VACV was shown to preferentially use the low-pH endosomal 
entry pathway, and addition of endosomal acidification inhibitor drastically reduced 
viral entry. Mercer et al (2010) later discovered that the IHD-J VACV strain utilized 
distinct forms of macropinocytosis for host-cell entry. The IHD-J strain is more 
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dependent on glycosaminoglycan binding for infection and less dependent on 
acidification of the endosome (Mercer et al., 2010). Recently, it has been discovered 
that the VACV A25 and A26 surface proteins are fusion suppressors for mature virions 
and determine strain-specific virus entry pathways into HeLa, CHO-K1 and L cells 
(Chang et al., 2010). Overall, both Vaccinia virus strains WR and IHD-J employed an 
entry strategy based on apoptotic mimicry, whereby they were disguised as apoptotic 
debris to enter host cells (Mercer et al., 2008). The ability of VACV to enter the host 
cell in this manner may be attributed to its relatively large size. VACV is comparable in 
size to apoptotic bodies that are macropinocytosed by professional phagocytes and other 
cell types (Mercer et al., 2008). This strategy has several advantages for the entry of 
virus: 1) it permits endocytic internalization of particles too big for other endocytic 
pathways. 2) it allows the virus to enter different cell types, as intake of apoptotic debris 
is common to most cells, and 3) this mechanism of entry prevents detection by the 
immune response (Mercer et al., 2008).  
 
The large genome of poxviruses allows replication to take place in the cytoplasm of 
infected cells as it encodes all of its own replication machinery. Poxvirus gene 
expression is divided into three phases: early, intermediate and late. The early genes 
encode factors needed for intermediate gene expression, while the intermediated genes 
encode factors required for late gene expression and the late genes encode structural 
proteins (for the packaging of the virus) and factors needed for early gene expression. 
Hence components required for transcription of early genes are pre-packaged inside the 
viral core, and expression of early genes begins as soon as the core is released into the 
cytoplasm. Early genes also encode proteins that are involved in viral DNA synthesis 
and defense against host cell immune responses. These immune defense molecules 
include proteins which alter the host cellular environment and inactivate cellular 
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immune responses in order to allow productive viral replication. Following early gene 
expression, replication of the genome begins with a nick in the covalent bond linking 
the two DNA strands of the Poxvirus genome (the double stranded DNA is now opened 
up and allows replication to occur). As replication occurs in the cytoplasm (away from 
the host cell replication machinery, in the nucleus) poxviruses express their own 
transcription factors and therefore, unsurprisingly, promoters of poxviruses can only be 
recognised by poxvirus RNA polymerase. Poxvirus replication is self-priming, 
producing large concatamers which are subsequently cleaved and repaired to produce 
intact viral genomes. Assembly of the virus occurs in the cytoskeleton of host cells but 
the assembly mechanism is not well understood and maturation of the virus may depend 
on the host cell (Moss, 2007). Once replication has been completed and the late genes 
have been expressed, viral crescents (composed of viral proteins and a host derived 
single lipid membrane) are formed. The viral genome and components required for 
initiation of early gene expression are packed into the viral crescents to form immature 
virions. Proteolysis of core proteins transforms the immature virion into intracellular 
mature virions (IMV) (Moss, 2007). Figure 1.2 shows a schematic diagram of the 
poxvirus replication cycle. 
 
1.2 Host Range 
 
1.2.1 Poxvirus Tropism 
 
Poxviruses show species specificities that range from narrow to broad. To date, the 
fundamental mechanisms that mediate the host tropism of individual poxviruses is still 
poorly understood. One of the challenges in identifying the specific poxvirus host 
tropism determinants is that at least 3 levels of tropism are exhibited, cellular tropism, 
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viral replication and pathogenesis. Each of these levels involves different aspects of 




Figure 1.2. Poxvirus replication cycle (McFadden, 2005). 
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Cellular tropism. In vitro studies have shown that most Poxviruses can bind a broad 
range of host cells and initiate infection but whether the infection is permissive 
(production of infectious viral progeny) or non-permissive (abortive replication) 
depends on specific poxvirus-cell pairing. In non-permissive cells, abortive replication 
may be due to the inability of the virus to circumvent innate intracellular barriers 
(McFadden, 2005). At least four categories of intracellular factors have been identified 
as potential restriction points for regulating whether a poxvirus is able to complete its 
replication cycle (McFadden, 2005). The first one is the status of the cell cycle as 
studies have shown that poxviruses encode growth factors that are capable of 
manipulating the cell cycle. The second one is the lineage and differentiation state of the 
infected cells, as some poxviruses are dependent on the precise differentiation state of 
the host cell. The third one is the presence/absence of complementing host factors that 
are required by the virus to complete its replication cycle. The last one is the signal 
transduction pathways used by the host cells to defend against virus infection. Many 
poxviruses have evolved to counteract the host cell immune response (McFadden, 2005).  
 
The second level of tropism refers to the levels of virus replication in specific host 
organs or tissues. This tropism can be influenced by the factors that mediate the cellular 
tropism as well as the host tissue-specific antiviral responses.  
 
The third level of tropism refers to the pathogenesis and symptoms of disease in the 
infected organism, which is influenced by the first and second level of tropism as well 
as the overall host immune response.  
 
In general poxvirus genes that are nonessential for the replication of the virus in tissue-
culture are called virulence genes. Following gene-knockout experiments, certain 
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poxvirus mutants were unable to replicate in previously permissive animal cell lines. 
These discoveries led to the investigation of specific virus/host interactions (Chung et 
al., 1998). As previously described, early genes are expressed by the prepackaged 
elements and are required for transcribing the later elements. Mutants have been 
identified which are capable of producing certain early proteins but do not express 
intermediate and late genes. This finding suggested that these mutations may have 
played an important role in the early stages of viral replication (Guerra et al., 2005). 
Among these mutants, several genes were found to be responsible for host range 
restriction in specific cell lines, and became known as the host range genes (hr genes) 
(Bradley et al., 2005).  
 
All poxviruses are predicted to encode a unique collection of host range genes. However, 
discovery of each host range gene is a result of targeted gene-knockout analysis, making 
identification and functional analysis of these genes complex and time consuming. For 
example, VACV mutated in a gene-knockout experiment was unable to grow in 
previously permissive RK-13 cells; this discovery of the VACV K1L gene, which is 
described more fully in chapter 3, section 3.1. Cowpox CP77 was discovered in a 
similar manner (Ramsey-Ewing et al., 1996). Most species within the Orthopoxvirus 
genus have a broad host range and are capable of full replication in a wide range of host 
cells (in vitro studies). This can probably be explained by the large coding capacity of 
poxviruses which allows them to encode a wide range of specific proteins to break the 
species barrier (Alcami et al., 2000). Most of the better characterised host range genes 
have been found to be conserved amongst the Orthopoxvirus genus, suggesting the 
importance of these genes in modulating host cell immune responses. Vaccinia virus 
(VACV), one of the most extensively studied Orthopoxvirus (as well as Poxvirus), has 
provided researchers ample data for studying host range genes. 
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1.3 Avipoxviruses  
 
1.3.1 Classification and Phylogeny 
 
As previously discussed, further classification of the Chordopoxvirinae is determined by 
the host organism of the virus. Members of the Avipoxvirus genus cause disease in 
poultry and wild birds. To date, poxvirus infection has been identified in more than 230 
of the known avian species. The following viruses have been identified as official 
members of the genus: Fowlpoxvirus (FWPV), Canarypoxvirus (CNPV), 
Pigeonpoxvirus (PGPV), Parrotpoxvirus (PRPV), Turkeypoxvirus (TKPV), 
Sparrowpoxvirus (SRPV), Starlingpoxvirus (SLPV), Houbarapoxvirus (HOPV), 
Macawpoxvirus (MCPV), Falconpoxvirus (FLPV), Albatrosspoxvirus (ABPV) 
(Jarminaet al., 2005). Phylogenetic analysis based on alignment of partial P4b 
nucleotide sequences of various isolates from different species showed that they group 
into 3 clades: A, B, C. (Jarmin et al., 2005).  
 
Two types of disease are seen following Avipoxvirus infection. The most common is the 
cutaneous form characterised by the formation of small lesions on the unfeathered 
region of the avian host. Avipoxvirus infection can also result in the diptheric form of 
disease characterised by formation of lesions in the mucous membranes of the 
respiratory tract. In poultry, the cutaneous form is often assoicated with low mortality 
whereas the diptheric form is associated with high mortality due to the occlusion of the 
oropharynx. Signs of Avipoxvirus infection have been noted in migratory birds such as 
quail and finch, which likely contribute to the distribution of the Avipoxvirus genus 
throughout the world (Kow, 1992).  
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In contrast to other poxvirus genera, the Avipoxvirus genus shows a restricted host-range 
and can only replicate in specific avian species and cell lines of avian origin. Most 
mammalian cell lines are non-permissive for avianpoxviruses. The only known 
mammalian cell line reported to be permissive was derived from syrian baby hamster 
kidney fibroblasts (BHK-21) suggesting that this cell line may lack factors/pathways 
that inhibit viral replication (Weli et al., 2005). As previously mentioned, Avian 
poxviruses do not share similarity with the other Chordopoxvirus genera regarding gene 
arrangement and host restriction. Most members of the Chordopoxvirinae show similar 
gene order within the conserved central region of the genome, whereas rearrangement 
of these conserved genes is seen in the Avipoxviruses. This suggests that the Avipoxvirus 
genus is the most divergent genus within the Chordopoxvirus sub-family  
(Gubser et al., 2004).  
 
1.3.2 Penguinpoxvirus (PEPV) 
 
In 1988, marine birds along the coast of South Africa were reported ill following an oil 
spill. African penguins brought into The Southern African Foundation for the 
Conservation of Coastal Birds (SANCCOB) were found to have lesions around the eyes. 
Virus isolated from these lesions was characterised using restriction enzyme analysis 
and electron microscopy, and the results were compared to other known avian 
poxviruses (Kow, 1992). Electron micrograph images of the isolated virus showed that 
it was a poxvirus and the morphology of virus was similar to that of FWPV. Restriction 
enzyme analysis and comparison to other known avian poxviruses including CNPV, 
FWPV and Parrotpoxvirus, confirmed that it was a novel avian poxvirus (Kow, 1992). 
Phylogenetic analysis revealed that the virus groups with Avipoxviruses in clade A, 
subclade A2 (Carulei et al., 2009). 
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Further characterization involved cell culture studies to investigate growth 
characteristics of PEPV in mammalian and avian cell lines (Stannard et al., 1998). 
Various cell lines, which included (CV-1 (monkey kidney), Vero (African green monkey 
kidney), HeLa (human cervical carcinoma), MDBK (bovine kidney), RK-13 (rabbit 
kidney), HEF (human embryo fibroblasts) and CEF (primary chick embryo fibroblasts)), 
were infected with PEPV. No increase in viral titre was observed and no infectious virus 
was obtained after a single passaging event. Visualisation of infected cells using 
electron microscopy revealed the presence of immature viral particles, indicating that 
virus maturation was blocked at a late stage of viral replication. Transient expression 
analyses were performed to determine the degree of virus maturation. Mammalian and 
avian cells, CV-1 (monkey kidney), Vero (African green monkey kidney), HeLa (human 
cervical carcinoma), MDBK (bovine kidney), RK-13 (rabbit kidney), HEF (human 
embryo fibroblasts) and CEF (primary chick embryo fibroblasts), were infected with 
PEPV and transfected with plasmid containing a reporter gene under the control of the 
Vaccinia virus P11 late promoter. The results showed variation in the level of reporter 
gene expression, suggesting that PEPV is more adapted to certain cell lines. A high level 
of reporter gene expression was detected in CEF and CV-1 cells suggesting a late block 
to viral replication in these cell lines whereas low levels of reporter gene expression was 
detected in HeLa, MDBK, HEF and RK-13 cells, suggesting an earlier block to viral 
replication in these cell lines (Stannard et al., 1996). This also indicated that PEPV is 
capable of expressing foreign antigens in mammalian cells which raised the possibility 
of using PEPV as a vaccine vector. The genome of PEPV has recently been sequenced 
and will provide a foundation for further investigation of host range specificity of PEPV 
(Carulei, unpublished data).  
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1.4 Poxviruses as Vaccine Vectors 
 
With the advent of the Human Immunodeficiency Virus (HIV) pandemic and reassorted 
influenza virus, novel vaccine vectors are continuously required in this vaccine versus 
virus battle, especially against these rapidly mutating viruses. Poxviruses have been 
used as vectors for the expression of antigenic proteins and the success of poxviruses as 
vaccine vectors is due to their ability to accommodate large foreign gene inserts as well 
as their unique immunological properties in eliciting long-term, protective, humoral and 
cell-mediated immune responses. Vaccinia virus vaccine was used successfully to 
eradicate smallpox (Fenner et al., 1988). However the VACV vaccine was found to 
cause adverse effects such as eczema vaccinatum, myocarditis and vaccinial 
encephalitis in immunosuppressed individuals and young children (Remichkova, 2010). 
These effects sometimes resulted in fatal complications and substantial morbidity 
causing concern about the safety of using VACV as a vaccine. These adverse effects led 
to the development of highly attenuated, replication deficient strains, Modified Vaccinia 
Ankara (MVA) and a highly attenuated Vaccinia virus strain NYVAC as well as the host 
range restricted Canarypoxvirus strain ALVAC. These vectors have good safety profiles 
and elicit strong immune responses against vectored antigens. 
 
1.4.1 Modified Vaccinia Ankara (MVA) 
 
MVA was derived from the Ankara strain of VACV by >500 passages in chicken 
embryo fibroblasts (CEFs). DNA sequencing and analysis revealed that 15% (30kb) of 
the parental viral genome was deleted from the termini and central region. Multiple 
genetic deletions and mutations resulted in loss of the ability to perform complete 
replication in most mammalian cells. To date, only two cell lines (BHK-21 and CEFs) 
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have been found to be permissive to MVA infection. In the late 20
th
 century, MVA was 
inoculated into more than 120 000 individuals in Germany during the Smallpox 
eradication campaign, with no reported adverse effects. Thus MVA is now considered to 
be a suitable platform for the next generation of safer recombinant poxvirus vectors and 
has been clinically tested against infectious diseases such as AIDS, malaria and human 
papillomavirus-associated cancer (Nájera et al., 2006). 
 
In nonpermissive cells, the MVA replication cycle is abolished during the late stage. 
Also, cytopathic effect (CPE) (cell function, metabolism and morphology) induced by 
MVA is minor compared with the wild type VACV strain. This may be attributed to the 
fact that MVA has lost 15% of its parental genome and may relate to the absence of the 
early proteins, for example the VACV K1L gene (see Figure 1.3). Many deleted or 
mutated genes are implicated in the modulation of the host response. It was assumed 
that these deletions and mutations are responsible for the replication-deficient 
phenotype of MVA. Comparing MVA to the Copenhagen strain of VACV, the left 
terminal region of the MVA genome contains 4 large deletions and many fragmented 
open reading frames. However the central conserved region remains intact with the 
exception of F5L, F11L and O1L genes, the function of these genes are still not well 
studied. The right terminal region contains 3 large deletions as well as many disruptions 
of open reading frames (see Figure 1.3) (Gómez et al., 2008). Despite its restricted 
replication capacity, MVA elicits a strong immune response, possibly due to the absence 
of the host range genes. The majority of these host range gene contribute to 
immunomodulation. Loss of these immunomodulatory genes result in a strong immune 






NYVAC, another attenuated strain of VACV, well-known for its safety profile, was 
originally derived from the VACV Copenhagen strain, and attenuated by targeted 
deletion of 18 open reading frames involved in host range, virulence and pathogenesis 
of the virus (Gómez et al., 2008). Thus NYVAC is replication deficient in cells of 
human, murine and equine origin, however CEFs and Vero cells are permissive to 
NYVAC infection. 
 
Figure 1.3 shows a comparison of the deleted genes of MVA and NYVAC. Certain 
genes are deleted in either NYVAC or MVA and some are absent from both viruses. In 
NYVAC infected cells, CPE was observed early after infection in a range of permissive 
and nonpermissive cell lines (Gómez et al., 2008). This indicates that the presence of 
CPE is independent of host range restriction. Rounding of the cells is dependant on the 
synthesis of early proteins, indicating that NYVAC is capable of producing early 
proteins in both permissive and nonpermissive cells. In nonpermissive cells, for 
NYVAC, there is a block in the virus life cycle prior to the formation of immature 
virions, whereas for MVA, the bock occurs after the formation of immature virions 
(Nájera et al., 2006). While MVA produces both early and late viral proteins, certain late 
viral proteins are not detected in NYVAC infected cells, however the absence of the late 
viral proteins is not due to a blockage in the transcription of these late genes, but rather 
at the level of translation. This feature has contributed to the safety of NYVAC, since it 
is unable to synthesize the late viral proteins needed for the assembly and formation of 
infectious viral particles under nonpermissive conditions.  
 
Apoptosis plays a key role in cellular defense against viral infection and poxviruses 
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encode certain proteins to counteract programmed cell death. Apoptosis is observed in 
nonpermissive cells infected with MVA or NYVAC that were previously permissive to 
the wild type VACV. This may reflect the loss of specific viral genes, for example, K1L, 
as will be discussed in Chapter 3, section 3.1. Deactivation of NF-κB is one of the 
mechanisms utilized by poxviruses to counteract apoptosis, and this mechanism may be 
mediated by the K1L protein (Nájera et al., 2006). However, the percentage of apoptotic 
cells following MVA infection is significantly lower than that following NYVAC 
infection. This may be due to the expression of different host range genes in MVA and 
NYVAC. This may be due to MVA expressing a certain late protein which inhibits 
apoptosis, or an early protein (possibly C7L) that plays a role in inhibiting apoptosis; 
which NYVAC does not have. C7L was deleted from NYVAC but remains intact in 
MVA (see Figure 1.3), and may therefore contribute to the differences in induction of 
apoptosis (Nájera et al., 2006). 
 
Even with these differences, NYVAC induces similar immune responses to MVA. In 
general MVA induces specific CD8+ T cell and CD4+ responses whereas NYVAC 
induces greater levels of CD4+ T cells. Thus for vaccination purposes, by using both 
vectors in prime/boost strategies it may be possible to produce broader cellular and 
humoral immune responses, which are required for vaccination strategies against HIV. 
Prime/boost strategies employing heterologous vectors, especially with recombinant 
poxviruses as the boost, have proven to be excellent regimens to elicit antigen-specific 
cellular immune responses. Despite the above mentioned advantages of MVA and 
NYVAC, pre-existing anti-VACV immunity in VACV vaccinated individuals 
(vaccinated during the global eradication of smallpox) may reduce the effectiveness of 









Due to the possibility of pre-existing anti VACV immunity, vectors based on poxviruses 
other than VACV have been extensively researched. Avipoxviruses are naturally 
replication deficient in most mammalian cells (BHK-21 cells are permissive to some 
Avipoxviruses), giving members of this genus a significant biosafety advantage in terms 
of vector development. Currently the two most well known vectors in the Avipoxvirus 
genus are Fowlpoxvirus (TROVAC) and Canarypoxvirus (ALVAC) (Tulman et al., 
2004). 
 
ALVAC was derived from a Canarypoxvirus isolated from a single pox lesion on an 
infected canary. The virus was attenuated by 200 serial passage in CEF cells. Like the 
attenuated VACV strains, ALVAC is capable of expressing foreign antigens in non-
permissive cells and eliciting strong immune responses. Initially ALVAC and TROVAC 
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were evaluated and developed to vaccinate birds against avian diseases. Use of these 
vectors has expanded to other veterinary and human vaccine applications. ALVAC 
vectors have been developed to express genes from rabies virus, canine distemper virus, 
feline leukemia virus, human immunodeficiency virus, simian immunodeficiency virus 
and Japanese encephalitis virus (Yu et al., 2006).  
 
During the development of HIV vaccines, studies showed ALVAC is capable of 
inducing early inflammatory responses in mice and guinea-pigs, in both the infectious 
and heat-inactivated forms, and is not influenced by the route of virus inoculation 
(intramuscular, subcutaneous or intravenous). This suggests that inactivated poxviruses 
are capable of retaining immunostimulatory properties (Boudet et al., 2001). The safety 
of an ALVAC-HIV vaccine consisting of 5 different ALVAC constructs was tested on 
1497 volunteers, of which less that 3% vaccinees showed severe local responses and 
less than 1% experienced severe pain or tenderness. Reactogenicity was not related to 
the inserted genes and did not vary between different constructs (de Bruyn et al., 2003). 
Various HIV subtype B Canarypox-HIV vector primes and boosters containing subunit 
glycoprotein 120 or 160 (gp120 or gp160) were evaluated in phase I and II clinical trials, 
and were shown to be safe and simultaneously elicit strong immune responses (Russell 
et al., 2007). In 2003, a phase 3 trial of an ALVAC-HIV (vCP1521) prime with a 
VaxGen bivalent gp120 AIDSVAX B/E boost took place in Thailand. 16402 healthy 
men and women between the ages of 18 and 30 were randomly chosen to participate in 
the trial. Preliminary results showed a statistically though mild protective efficacy of 
31% in the vaccinated group. The results showed a modest benefit in reducing the risk 
of HIV infection but further investigation on whether the efficacy decreased over the 
first year of vaccination or whether the efficacy may be greater in individuals at lower 
risk is still to be examined (Reks-Ngarm et al., 2009). 
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1.5 Project Motivation 
 
According to the latest World Health Organisation report, 33.4 million people currently 
live with HIV/AIDS worldwide of which 67% of the total number of people infected 
with HIV lives in sub-saharan Africa (UNAIDS, 2009). Therefore, there is an urgent 
need for a HIV vaccine. Although existing poxvirus-based vaccine vectors have shown 
promising results in clinical trials (Russell et al., 2007; Reks-Ngarm et al., 2009), pre-
existing VACV immunity and past Orthopoxvirus-based complications have stimulated 
the search for safer, novel poxvirus vectors.  
 
PEPV, a novel, local avian poxvirus has the potential for development as a vaccine 
vector due to its host range restriction and non cross-reactivity with Orthopoxviruses 
(Stannard et al., 1996). However, to construct a recombinant poxvirus one cannot 
simply clone the foreign gene of interest directly into the viral genome; as poxvirus 
DNA is large (180~350kb) and noninfectious. The standard method of producing a 
recombinant virus is to infect cells with the virus and transfect these same cells with a 
transfer vector. The transfer vector would contain the gene of interest together with a 
selection marker, flanked by sequences that are homologous to a nonessential gene of 
the virus. Once both virus and transfer vector are inside the cell homologous 
recombination can take place between the flanking sequences of the transfer vector and 
the viral genome and the foreign gene of interest is transferred from the transfer vector 
into the nonessential region of the virus (shown in Chapter 4, Figurea4.1). The purpose 
of the selection marker is to select the recombinant virus from the wild type virus.  
. 
As discussed in section 1.3.2, PEPV is unable to complete its replication cycle in any of 
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the cell lines tested. This characteristic could be used in the construction of recombinant 
PEPV. VACV K1L protein is capable of rescuing the growth of mutant VACV and wild 
type MVA in RK-13 cells (see Chapter 3, section 3.1). It is possible that transient 
expression of VACV K1L gene could rescue the growth of PEPV in RK-13 cells. The 
aim of this study was to rescue the growth of PEPV in RK13 cells and hence utilise K1L 
as a selective marker for the construction of recombinant PEPV. The first objective was 
to confirm that RK-13 cells are non-permissive for the growth of PEPV by constructing 
a standard growth curve.  
 
The second objective was to construct a transfer vector capable of transient expression 
of VACV K1L protein in RK-13 cells infected with PEPV. The TK gene was used as a 
site of insertion. TK sequences were PCR amplified from PEPV and cloned into the 
plasmid pUC21. K1L and the reporter gene GUS were inserted between these flanking 
sequences in subsequent cloning steps.  
 
The third objective was to rescue PEPV growth in RK-13 cells which were infected 
with PEPV and transfected with the transfer vector. If homologous recombination were 
to take place, all recombinant virus containing K1L would complete its replication cycle 
in RK-13 cells while remaining wtPEPV will be unable to complete its replication cycle.  
 
The final objective was to isolate a recombinant PEPV containing K1L and GUS. The 
long term goal of this project is to construct a recombinant PEPV which expresses  
HIV-1 genes and could be used as a HIV-1 vaccine. 
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The long term goal of this project is to construct a recombinant PEPV. For this purpose 
it is necessary to prepare PEPV stocks of high titre and known concentration. PEPV was 
required for growth curve experiments to determine whether it is able to complete its 
replication cycle in RK-13 cells (Chapter 3) and for the construction of recombinant 
PEPV (Chaptera5). Although a number of cell lines (CV-1 (monkey kidney), Vero 
(African green monkey kidney), HeLa (human cervical carcinoma), MDBK (bovine 
kidney), RK-13 (rabbit kidney), HEF (human embryo fibroblasts) and CEF (primary 
chick embryo fibroblasts)) have been tested for permissively to PEPV growth, a suitable 
cell-line that can be used to grow PEPV is yet to be identified (Stannard et al., 1998). At 
present the only known method of growing up and harvesting PEPV is to grow the virus 




Figure 2.1. Diagram showing the contents of a typical fertilized egg. 
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Figure 2.1 shows a diagram of a typical fertilized egg. The chorioallantoic membrane 
consist of an outer layer of stratified epithelium, the respiratory surface of the egg and 
an inner layer of endoderm (lining the allantoic cavity). The use of chick embryos for 
poxvirus diagnosis was first described in 1937, and has been used in poxvirus 
diagnostics (Joklik, 1962). Some poxviruses such as Parapoxviruses, Yatapoxviruses 
and Molluscipoxviruses do not form pocks on CAM whereas Orthopoxviruses 
(including Variola virus, Monkeypox virus, Cowpox virus and Vaccinia virus), 
Avipoxviruses, Leporipoxviruses and Capripoxviruses produce pocks on CAMs (Mercer 
et al., 2007).  
 
Different species of poxvirus show different characteristics of pocks produced on the 
chick CAM (Fenner et al., 1989). Most of the Orthopoxvirus strains, (Cowpox virus, 
Monkeypox virus, various strains of Vaccinia virus and Elephantpox virus) produce red 
pocks on CAMs (mutant strains of these poxviruses produce white pocks), whereas 
Variola virus produces typical white pocks on chick CAMs (Baxby, 1969; Baxby et al., 
1977). The Avipoxviruses produce typical white pocks and the infected CAMs are 
generally thickened at the area of inoculation (Tripathy, 2009). Interestingly, the pock 
morphology can be influenced by changing the incubation temperature of the egg, 
positioning of CAM during incubation and the source and age of the chick embryo. The 
fact that there is a particular age of embryo (generally 10~12 days) which produces a 
high proportion of a typical pock suggests the need for a particular developmental stage 
in the embryo, however the precise physiological mechanism being affected by the 
environmental change is not well understood (Baxby, 1969).  
 
In this study, the method used for the isolation of PEPV was a modification of the 
method used by Joklik (1962) and is described in sections 2.2.2 and 2.2.3. 
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2.2 Materials and Methods 
 
2.2.1 Inoculation of Chick Chorioallantoic Membranes (CAMs) 
 
Fertilized eggs that were 7 ~ 12 days old were ordered through the UCT Medical School 
Animal Unit (Ethis Approval No. AEC 007/020). Eggs were incubated at 37
o
C for the 
duration of viral growth; this provided favorable conditions for the growth and 
development of the chick embryo, and hence, good nutrition for PEPV, which grows on 
the chorioallantoic membranes (CAM). 
  
Eggs were first observed with an egg-candler to locate suitable regions for PEPV 
infection. Infection must not take place directly on the blood capillary but nearby. A 
pencil mark was made at this position and also on the central region of the air sack. An 
egg pricker was used to puncture the shell on the marked regions. A drop of phosphate 
buffered saline (PBS) containing penicillin and streptomycin [20ml of 1xPBS (137mM 
NaCl, 2.7mM KCl, 100mM Na2HPO4, 2mM KH2PO4, pH 7.2) with 200µl of P/S 
(1000U/ml Penicillin, 10mg/ml Streptomycin)] was dropped at the dorsal opening and 
allowed to enter the egg by creating a suction force, using a rubber bulb, at the air sack 
opening. This resulted in the dropping of the CAM. PBS is a water based salt solution, 
which is used to maintain a constant pH. It is isotonic and non-toxic to cells. Therefore 
it is used as a diluent or to rinse flasks of cells. The eggs were left at 37
o
C for 1.5 hours. 
 
A PEPV viral stock (obtained from the Department of Clinical Laboratory Sciences, 
Virology Division, UCT) was diluted using PBS as the pH value of PBS (pH 7.2) is the 
same as that of living tissue. It was essential to first dilute the viral stock prior to 
infection, as infection with concentrated viral suspension onto the CAM could result in 
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killing of the chicken embryo and hence reduction in growth of the virus. 100µl of the 
diluted viral stock was injected onto the CAM, using a syringe with surgical needle, at 
the marked dorsal opening. To prevent contamination of the CAM through the dorsal 
opening, melted candle wax was placed next to the dorsal opening. As soon as the wax 
cooled down, a wooden tongue compressor was used to spread the wax across the dorsal 
opening. If heated wax was immediately placed across the dorsal opening, the liquid 
wax would damage the infected CAMs.  
 
Lastly, eggs were rotated by hand to allow the viral suspension to spread evenly across 
the CAM. Eggs were then incubated at 37
o
C for 96 hours.  
 
2.2.2 Viral Harvest 
 
The following procedure was carried out, as described by Daria Kow (Kow, 1992). 
Sterile, sharp scissors were used to cut along the sides of each PEPV infected egg from 
the air sac opening. The dropped CAM was removed from the egg shell using sterile 
forceps. The infected CAM was placed in a physiological saline (0.85% w/v sodium 
chloride) solution immediately after it had been detached from the shell. A series of 
washes in saline solution removed blood and other contaminants from the membranes. 
A few CAMs were spread out onto Petri dishes and examined for the presence of pocks. 
Washed CAMs on the Petri dishes were photographed. 
 
Four to five infected CAMs were transferred to a sterile McCartney bottle with glass 
beads. 5ml of ice-cold McIlvain’s solution (0.1M citric acid, 0.2M disodium hydrogen 
orthophosphate, pH7.4) was added into each bottle. McIlvain’s solution was used to 
create a hypotonic environment for suspension of the viral particles (Fenner, 1989). 
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Bottles were then balanced via the addition of ice-cold McIlvain’s solution and shaken 
vigorously by hand for two minutes. Membranes could be placed at 4
o
C overnight or 
immediately processed as described below.  
 
The bottles were centrifuged at 800 rpm for 10 minutes. The purpose of centrifugation 
was to pellet the debris and contaminants and release virus into the McIlvain’s solution. 
Supernatants were recovered and transfered into another sterile ice-cold McCartney 
bottle. The bottles with recovered supernatants were kept on ice to maintain virus 
viability. 5ml of ice-cold McIlvain’s solution was added again to the bottle with CAMs 
and glass beads. The bottles were shaken vigorously by hand for two minutes and 
centrifuged again at 800 rpm for 10 minutes. The supernatants were recovered and 
added to the previously recovered supernatants. These steps were repeated 3~4 times to 
extract the maximum amount of virus possible from the CAMs. The bottles containing 
recovered supernatants were balanced with ice-cold McIlvain’s solution and centrifuged 
at 1500 rpm for 30 minutes. This was to pellet any remaining CAM tissue debris. The 
supernatants were then transferred to sterile Beckman JA20 centrifuge tubes. 
 
Centrifuge tubes were balanced and 5ml of 36% (w/v) sucrose solution was carefully 
pipetted to the bottom of the centrifuge tubes. The high density of the sucrose solution 
created a cushion, which trapped any excess CAM debris during centrifugation through 
the cushion. Centrifuge tubes were centrifuged for 1 hour at 11000 rpm at 4
o
C in a 
Beckman J2-21 centrifuge. After centrifugation, supernatants were discarded and the 
pellets were resuspended in 0.5ml of Tris-EDTA buffer (10mM Tris, 1mM EDTA, pH 9). 
Sucrose dextran gradients were used to further purify the viral extract. 10ml of 10% 
(w/v) dextran was first pipetted into each centrifuge tube, 5ml of 36% (w/v) sucrose 
solutions was then carefully pipetted beneath the dextran solution and, finally, the viral 
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suspension was placed on top of the dextran layer. The tubes were centrifuged at 11000 
rpm for 1 hour at 4
o
C. The supernatants were removed and pellets were resuspended in 
0.5ml Tris-EDTA buffer (pH 9). The viral suspension was aliquotted into several 1.5ml 
microfuge tubes (100µl per tube) and stored at -80
o
C to maintain virus viability. 
 
2.2.3 Titration of PEPV  
 
Titration was carried out to quantify the viable virus. Viral titres are standardly 
expressed as pock (or plaque) forming units per milliliter (pfu/ml). 
 
One of the stock PEPV aliquots (100µl) was retrieved from the -80
o
C freezer, thawed 
and diluted with 900µl PBS solution (10 fold dilution). A dilution series of 10
-1
 to  
10
-5




 were used for the titration. One membrane 
was inoculated with PBS (uninfected). 
 
A total of 12 eggs were infected, two eggs for the 10
-2
 dilution, three eggs for each 




 dilutions and one egg inoculate with PBS only. Inoculation 
was performed as described in section 2.2.1 and the CAMs were harvested as described 
in section 2.2.2. Membranes infected with a dilution which gave countable pocks were 
used to determine the virus titre. The pocks were counted on each membrane and the 
average was determined.  
The virus titre was calculated as: 
Virus titre (pfu/ml) = Number of pocks formed on CAM x dilution factor x 10 (as 100µl 




2.3 Results  
 
A PEPV stock was made from starting material (10
7
 pfu/ml) obtained from the Division 









 pfu/ml) with 1X PBS and each dilution was 
used to inoculate 20 chick CAMs as described in section 2.2.1. Four days post 
inoculation of the CAMs, PEPV was harvested from all 40 CAMs as described in 
section 2.2.2, aliquotted into 1.5ml microfuge tubes (100μl per tube) and stored at -80
o
C. 
For the quantification of the virus, titration was carried out on one of the frozen aliquots 
as described in section 2.2.3. Figure 2.2 shows representative membranes from this 
titration.  
 
 (A)                             (B) 
 
 (C)                                (D) 





 and C) 10
-5
 or left uninfected D). 
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A clear membrane was seen for the uninfected CAM (Figure 2.2D). Individual pocks 
were seen on the CAM infected with the highest dilution of PEPV (Figure 2.2C). As the 
concentration increased the number of pocks increased and gradually merged with one 
another (Figure 2.2B) and in the end formed a confluent layer of pocks (Figure 2.2A). 
Membranes infected with the 10
-5 
dilution were used to determine the virus titre. Pocks 
were counted and the average determined as listed in Table 2.1. An average of 30.5 
pocks (pera100μl) were counted from the eggs infected with the 10
-5
 dilution (see Table 
2.1). The titre was calculated by multiplying the number of pocks (30.5) by the dilution 
factor (10
5
) to give a value of 3.05x10
6
 pfu (pocks forming unit)/100μl. This was 
converted to pfu/ml by multiplying by 10. The final titre obtained was 3.05x10
7 
pfu/ml. 
The final viral volume obtained from the initial viral stock preparation was 1.5ml, 




Table 2.1. Table showing numbers of pocks on PEPV infected CAMs and 
subsequent determination of viral titre (pfu/ml) (Stock 1) 
Dilution 
 
No. of Pocks (per 100μl) Average No.  
Of Pocks per 
100μl 
Average 






































Later in the project a second viral stock was prepared in the same manner and titre was 
determined as shown in Table 2.2. However, when determining the titre of the second 
viral stock, the dilution series was extended to 10
-6
. This is because, in the first titration, 
the only dilution factor that one could use for determining the titre of PEPV was 10
-5
, 
which produced 10~100 pocks on the surface of PEPV infected CAMs. All the other 
dilution factors produced too many pocks on the surface of the CAM for accurate 
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counting of pocks. Therefore, further dilution would ensure single pocks, for accurate 
determination of  the titre of PEPV. 
Table 2.2. Table showing numbers of pocks on PEPV infected CAMs and 
subsequent determination of viral titre (pfu/ml) (Stock 2) 
Dilution 
 
No. of Pocks (per 100μl) Average No.  
Of Pocks per 
100μl 
Average 


























 3 10* 3 3 3.0x10
7
 
*outlier, therefore not considered in the average No. of Pocks. 
 
This stock gave an average number of 17.5 pocks (per 100μl) on 10
-5 
dilution and 3 
pocks (per 100μl) on 10
-6





 pfu/ml. The dilution of 10
-5
 gave >10 pocks/membrane, which would be more 
accurate than using figures <10 pocks / membrane. However, one egg was rotten and 
only two values could be used. Therefore for future work, one would suggest to use 
more than 3 CAMs per dilution. For the purpose of this project, the viral titre of stock 2 
was estimated to be 2x10
7
 pfu/ml. The final viral volume obtained from the initial viral 







The pocks produced by PEPV in this study, showed a typical white pock of 1~2mm in 
diameter. This is similar to the appearance of pocks produced by Fowlpox virus (Kow, 
1992), and is consistent with previous work done on PEPV (Kow, 1992).   
 





 pfu/ml and 2x10
7
 pfu/ml). During the titration of the 
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harvested PEPV stock, for both experiments, 2 of the 3 CAMs had to be discarded. It 
would therefore be advisable to use more than 3 CAMs in the future for a more precise 
determination of viral titre. To accurately determine the titre of PEPV on CAMs, one is 
required to count individual pocks, which is only possible if there are less than 100 
pocks per CAM. It is therefore important to use a large dilution series in the titration of 
a large virus stock preparation, as inoculation of CAMs with less diluted PEPV will 
result in formation of more than 100 pocks per CAM, which cannot be considered for 
the determination of the titre, as a large number of pocks on a single CAM will result in 
the merging of individual pocks which cannot be accurately counted (shown in Figure 
2.2A and B).  
 
In this study, the amount of virus harvested from CAMs infected with PEPV is 
relevantly low compared to those infected with Orthopoxviruses. Vaccinia virus,  virus 
and Cowpoxvius were shown to produce 10
8
 pfu/CAM (Joklik, 1962), whereas in this 
study, 40 CAMs produces 10
7
 pfu in total (4.6x10
7
 pfu and 3.0x10
7
 pfu respectively). 




 pfu of virus was inoculated 




pfu of virus was inoculated onto the 
CAM. Inoculation with higher concentrations of PEPV was attempted, however, it 
ultimately killed the chick embryos and no pocks could be harvested from the infected 





 pfu of recombinant virus (Coupar et al., 2006; Nájera et al., 
2006; Elahi et al., 1998; Zheng et al., 2006). Hence if one intends to construct a 
recombinant PEPV as a potential vaccine candidate, growing on chick CAMs may not 
produce sufficient virus for a clinical trial. If a recombinant PEPV could be constructed 
which grows in RK-13 cells, it may be possible to generate stocks if higher titre in these 
cells. 
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3.1.1 Discovery of VACV K1L gene 
 
Host range genes were discovered by gene-knockout analysis, as described in section 
1.2.1. Mutants display restricted ability to grow in cell lines permissive to wildtype 
virus infection. By comparing the mutant genomes to the wild type virus genome, one 
could identify the gene or genes responsible for viral tropism in specific cell lines. A 
mutant strain of Vaccinia virus (wild type strain: Copenhagen) was discovered to be 
non-permissive in rabbit fibroblast (RK-13) cells and certain human cell lines (Perkus et 
al., 1990). Transient expression of a certain VACV gene was found to be capable of 
rescuing VACV infection in the above mentioned cells. This led to the discovery of the 
host range gene K1L (Rosel et al., 1986).  
 
3.1.2 Action of the VACV K1L Gene Product 
 
K1L protein is expressed during the early phase of viral replication and in the absence 
of K1L protein, viral replication is abolished. Furthermore, studies have shown that both 
viral and host protein synthesis is rapidly shut down in K1L
-ve
 Poxvirus infected cells. 
However early viral mRNAs and proteins are still detected in the host cytoplasm 
(Ramsey-Ewing et al., 1996).  
 
K1L has been demonstrated to inhibit host cell immune responses by inhibiting 
activation of the classical NF-κB pathway (Figure 3.1). This pathway regulates the 
expression of genes involved in immune responses, inflammation, apoptosis and 
proliferation. Activation of the NF-κB pathway is initiated through many signals 
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including pathogen infection, proinflammatory cytokines, and exposure to mutagen. 
Activation of the pathway begins with the phosphorylation of IκB kinase (IKK) which 
subsequently phosphorylates IκBα. Phosphorylated IκBα is then polyubiquitinated and 
targeted by the 26S proteosome. Degradation of IκBα by the proteosome eventually 
releases the NF-κB transcription factor. A Key step in the NF-κB pathway is the 
phosphorylation of IκBα by IKK. By comparing the K1L knock-out mutant with wild 
type virus in a previously permissive cell line, it was deduced that K1L has the ability to 
inhibit the activation of the NF-κB pathway by preventing the degradation of IκBα. 
However, inhibition of host NF-κB activation does not seem to be related to the host 
range function of K1L as inhibition of NF-κB activation was observed during infection 








Interestingly, the K1L gene shows functional correlation with another host range gene, 
CP77 found in Cowpox virus. The replication defect of K1L-deleted Vaccinia virus 
mutants in most human cells and RK-13 cells was complemented by the CP77 gene in 
growth rescue experiments (Meng et al., 2006). However, limited sequence homology 
was observed between these 2 host range genes.  The only homology seen between the 
two genes is that both genes consist of multiple ankyrin repeats (ANKs), a common 33-
residue protein motif, which is involved in mediating protein-protein interactions. This 
motif can be found in proteins responsible for cytoskeletal organisation, cyclin-
dependent kinase inhibition, signal transduction and transcriptional regulation. The 
structures of the ANK-containing proteins are well conserved, however each of these 
proteins interacts specifically with its binding partner. Binding specificity is a result of a 
variable surface residue within the ankyrin repeats and of the stacking of different 
numbers of repeats in one protein (Meng et al., 2006). Thus considering the only 
homology of K1L protein and CP77 protein are these ANK sequences, the variable 
surface residues on the repeats may play a key role in the specific host range function of 
K1L protein.  
 
K1L protein was found to interact with ACAP2, a human GTPase activating protein. 
This protein is a homolog of a rabbit protein previously identified to bind to K1L 
(Bradley et al., 2005). Therefore interaction with ACAP2 was hypothesized to be the 
host range determinants of K1L. An investigation was then conducted to determine 
which of the ANKs are essential for K1L to maintain its function (Meng et al., 2006). 
Through deletion and base substitution, it was found that ANK6 and the C-terminal of 
non-ANK residues are clearly not required, as deletions in these regions do not affect 
VACV replication in HeLa cells. ANK4 and ANK5 are required for maintaining the 
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structure of K1L protein as deletion of either one of these two ANK sequences 
abolished VACV replication while substitution with functionally unrelated ANKs 
restored the VACV replication. Residues in ANK1 and the C-terminal regions of ANK2 
and ANK3 were found to be essential for the function of VACV replication in HeLa 
cells. These ANK sequences are located in different regions of the K1L gene, but the 
overall protein structure of K1L showed that the tertiary structure of the product of these 
ANKs sequences were positioned at the same region in the K1L protein. Substitution at 
these regions resulted in disruption of the binding surface and reduction in replication of 
VACV. Although substitution at these regions reduced VACV replication, it seems these 
substitutions do not participate in the host range function of K1L, as substitution 
reduced replication in both permissive and non permissive cells. However, two vital 
residues were identified: phenylalanine 82 and serine 83. Substitution of either residue 
reduced the growth rate but substitution of both residues completely abolished viral 
replication in HeLa cells (Meng et al., 2006).  
 
Interestingly, deletion or substitution at certain ANK sequences may not affect VACV 
replication in HeLa cells (cells of human origin) but results in a loss of replication in 
RK-13 cells (rabbit kidney fibroblast cells). The N-terminal region of ANK2 and ANK3 
as well as the entire ANK5 and c-terminals of non-ANK sequences are not essential for 
viral replication in HeLa cells, but substitution or deletion in these regions results in 
termination or reduced viral replication in RK-13 cells. In addition, only substitution of 
both phenylalanine 82 and serine 83 will result in termination of viral replication in 
HeLa cells, but substitution of either residue will terminate replication in RK-13 cells. 
These results indicate that host restriction in RK-13 and human cell lines are different. 
The mechanism of restriction has not yet been elucidated. Interestingly, ACAP2 binding 
is not sufficient for the host-range function as previously hypothesized. Substitution of 
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the phenylalanine 82 and serine 83 residues of the ankyrin repeats resulted in abolishing 
the host-range function but still allowing the K1L protein to bind to ACAP2. Thus there 
must be other mechanisms that determine the K1L host range function (Meng et al., 
2006).  
 
It was recently discovered (Willis et al., 2009) that, K1L, CP77 and C7L host range 
proteins play a role in the PKR-elF2α pathway (see Figure 3.2). Both CP77 and C7L, 
capable of complementing K1L deleted Vaccinia mutants, have been shown to inhibit 
PKR (protein kinase receptor ) activation (Willis et al., 2009). The PKR-elF2α pathway 
is involved in down regulating protein synthesis and hence preventing virus replication. 
The key protein that mediates this pathway is the eukaryotic translation initiation factor 
2 (elF2α). In uninfected cells, elF2α remains in the inactive unphosphorylated state. 
Activated (phosphorylated) elF2α inhibits protein synthesis by preventing translation 
initiation. Various proteins have been identified which phosphorylate elF2α, including 
PKR. In virus infected cells, PKR is commonly found to mediate the phosphorylation of 
elF2α and hence prevent viral transcription. Poxvirus proteins including K1L have been 
found to inhibit the PKR- elF2α pathway by binding to PKR itself or its DNA sequence 
and prevent its from being transcribed in order to prevent PKR activation. K1L was 
found to inhibit PKR protein activation by binding to PKR (Willis et al., 2009). Further 
investigation showed that a substitution mutation at the ANK2 surface residue resulted 




Figure 3.2. The classical PKR- elF2α pathway (Holcik and Pestova, 2007) 
 
The CP77, K1L and C7L proteins complement each other to allow for Vaccinia virus 
replication in HeLa cells, but only K1L and CP77 are capable of complementing each 
other to allow for replication in RK-13 cells. All 3 proteins play a role in inhibiting PKR 
activation, although only CP77 and K1L possess ankyrin repeats. One could 
hypothesize that these two proteins utilise a similar molecular mechanism to alter PKR 
activation, whereas C7L may utilise an alternative pathway. One can speculate that the 
specificity of the surface residue in the ankyrin repeat of K1L and CP77 may play an 
important role in host range function in RK-13 cells, due to specific protein-protein 
interaction with PKR (Willis et al., 2009). 
 
As reported previously, PEPV is unable to complete its replication in any of the cell 
lines tested (Stannard et al., 1998). However, studies have shown expression of VACV 
K1L gene can rescue the growth of certain Poxviruses in RK-13 cells and hence been 
used as a selective marker for selecting recombinant plasmid (Sutter et al., 1994; Staib 
et al., 2000; Meng et al., 2006). The hypothesis in this thesis is that transient expression 
of VACV K1L can rescue the growth of PEPV in RK-13 cells. VACV K1L, cloned into 
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a transfer vector, can be used both to rescue the growth of PEPV in RK-13 cells and also 
as a selective marker for selecting recombinant PEPV. However, growth curves have not 
been generated to confirm that RK-13 cells are not permissive for PEPV. Thus, for the 
purpose of this project, it is important to clarify that RK-13 cells are not permissive for 
PEPV so that VACV K1L can be used to rescue the growth of PEPV in RK-13 cells and 
hence select for the recombinant PEPV. 
 
Growth curves have been used widely to study the growth of virus under different 
conditions such as determining the growth of Poxviruses in different cell lines (Drexler 
et al., 1998). Moreover, growth curves have been used in determining the function of 
Poxvirus host range genes by examining the effects of partial gene knockouts or by 
replacing certain region of the host range genes with homologous repeats on the growth 
of Vaccinia virus (Meng et al., 2006). This chapter describes experiments carried out to 
investigate whether or not RK-13 cells are permissive for PEPV. To achieve this, a 
standard growth curve was generated to monitor the change in titre of PEPV in RK-13 
infected cells over a period of 6 days. A second growth curve was generated in this 
study to examine if PEPV is capable of adapting to RK-13 cells after multiple passages. 
 




Rabbit Kidney cells (RK-13) were supplied by American Type Culture Collection 
(ATCC). An aliquot of cells was seeded into 10ml of DMEM with 10% FCS (foetal calf 
serum), 1% P/S (1000U/ml Penicillin, 10mg/ml Streptomycin) and 0.1% Fungin, in a 
75cm
3
 flask. Flasks were then incubated at 37
o
C, 5% CO2. 
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For cell passaging, the medium was first discarded and the cells rinsed with PBS 
solution to remove any trace of serum which may contain trypsin inhibitor. 2ml of 1x 
Trypsin was added to the flask, which was incubated at 37
o
C for 10 minutes. The 
purpose of the trypsin was to release the seeded cells from the flask. After 10 minutes, 
3ml of DMEM + 10% FCS was added to the contents in the flask to neutralize the 
trypsin. The contents were then transferred to a sterile 15ml tube.  
 
From the 15ml tube, 1µl was added to 9µl of trypan blue, carefully mixed and 
transferred to a gridded slide, to be observed using a microscope. The purpose of this 
action was to count the number of cells present in the 15ml tube. It was vital to know 
the number of cells harvested, as known numbers of cells were required to be seeded 
into fresh plates or flasks, depending on the requirement of the experiment.  
 
Known numbers of cells were then transferred to the flask or plates, and the required 
amount of medium + FCS + P/S was added. 
 
3.2.2 Viral Growth in RK-13 Cells 
 
3.2.2.1 Poxvirus Infection of RK-13 Cells 
 
Infectious virus was diluted with DMEM containing PS and Fungin (presence of FCS 
would inhibit virus adsorption). The medium in a 25cm
3
 flask or in the wells of a 6-
well plate was removed, the cells were rinsed with 1XPBS and DMEM with P/S and 
fungin was added to each well or flask. Cells were infected with pox virus using 
different MOIs, (multiplicity of infection = ratio of infectious virus particles to cells). 
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Plates or flasks were incubated at 37
o
C for 1.5hrs~2hrs for the virus to be adsorbed. 
Once the virus had been adsorbed, the medium was removed and the cells were 
rinsed with 1xPBS gently. DMEM containing 2%FCS was added (1 ml per well and 
2.5 ml per 25cm
3
 flask) and the cells were incubated at 37
o
C at 5% CO2 
 
3.2.2.2 Harvesting of Poxvirus 
 
To harvest virus, plates or flasks with infected cells were frozen at -20
o
C. Once all the 
cells were frozen, they were then thawed at room temperature. This procedure was 
performed 3 times to lyse the cells and release the virus. The lysates were transferred 
to sterile 15ml tubes or 1.5ml microfuge tubes and stored at -20
o
C. To passage the 
harvested virus, harvested virus was used to infect fresh cells as described in section 
3.2.2.1. 
 
3.2.2.3 Growth Curve of PEPV in RK13 Cells 
 
The growth curve experiments were performed, firstly to confirm Stannard’s 
observation that RK-13 cells are not permissive for PEPV (Stannard et al., 1998) (see 
section 3.2.2.3.1) and, secondly, to determine whether PEPV can adapt and complete 
its replication cycle in RK-13 cells after multiple passages (see section 3.2.2.3.2). 
 
3.2.2.3.1 Standard Growth Curve of PEPV in RK-13 Cells 
 
RK-13 cells were seeded into seven 25cm
3
 sterile tissue culture flasks. Each of the 
flasks was infected with 3x10
5
 wtPEPV. Infection procedures were as described in 
3.2.2.1. Once DMEM with 2%FCS, P/S and Fungin was added to the flasks, one of 
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the flasks was immediately stored at -20
o
C; this flask was labeled T0. The rest were 
incubated at 37
o
C. Each day one of the flasks was removed from the incubator and 
stored at -20
o
C. These flasks were labeled as T1, T2 and so forth. Once all the flasks 
had been removed from the 37
o
C incubator, virus was harvested as mentioned in 
3.2.2.2. Harvested virus was titrated on chick CAMs, as described in section 2.2.3. 
A growth curve was generated from the titre of virus found at each time interval to 
determine if wtPEPV was able to grow in RK-13 cells. 
 
3.2.2.3.2 Growth Curve to Examine whether wtPEPV Adapts to Growth in 
RK-13 Cells Upon Multiple Passages  
 
RK-13 cells were seeded into two 25cm
3
 sterile tissue culture flasks. Both flasks 
were infected with wtPEPV of known titre (3x10
5
 pfu). Infection procedures were 
as described in 3.2.2.1. Once DMEM with 2%FCS, P/S and Fungin was added to 
the flasks, one of the flasks was immediately stored at -20
o
C, this flask was labeled 
as P0. The other flask, labeled as P1 was incubated at 37
o
C for 3 days. After 3 days, 
virus was harvested as described in section 3.2.2.2. One fifth of the harvested virus 
was used to infect RK-13 cells in another freshly prepared 25cm
3
 flask. The 
remaining contents were stored at -20
o
C. This procedure was repeated until the 
virus had been passaged for 5 times.  
 
Once the virus had been passaged in RK-13 cells for 5 times, the harvested virus 
was titrated on chick CAMs, as described in section 2.2.3. A growth curve was 
then generated from the titre of virus found in each passage to determine if 
wtPEPV was able to adapt and grow in RK-13 cells after several passages. 
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3.3 Results  
 
3.3.1 Growth Curve of PEPV in RK-13 cells 
 
A growth curve was generated as described in section 3.2.2.3. The growth of PEPV was 
monitored from Day 0 to Day 6. Each 25cm
3
 flask was infected with 3x10
5
 pfu of PEPV. 
Once the virus was harvested from the infected flasks, virus from each time point was 
diluted 10 fold and 100 fold, i.e. 3 different viral dilutions. A total of 63 eggs were 
infected, three eggs for each dilution and 7 time points. Four days post inoculation, 
infected CAMs were spread onto petri dishes for examination of pock formation. The 
virus titre was calculated for each time point and a growth curve was drawn up from this 
data (see Figure 3.3). 
 
 
Figure 3.3. Growth curve to examine the growth of PEPV in RK-13 cells. Seven 
flasks of RK-13 cells were infected with 3x10
5
 pfu/flask of PEPV. At each time point, a 
flask was frozen. At Day 6, the virus from all flasks was titrated on chick CAMs 
(expressed as pfu/ml). 
 
Growth curve to test for growth of 
PEPV in RK-13 cells 
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Figure 3.3 shows a 100-fold difference in amount of virus recovered on Day 0 
compared to what was added (3x10
5
 pfu/flask). A dramatic decrease in viral 
concentration from 1000 pfu/ml at day 0 to 100 pfu/ml at day 1 was observed. The viral 
concentration gradually decreased and eventually was undetectable on Day 6.  
 
3.3.2 Growth Curve to Examine Whether wtPEPV Adapts to Growth in RK-13 
Cells Upon Passage in RK-13 Cells 
 
It was of importance to investigate whether PEPV is able to adapt to growth in RK-13 
cells after multiple passages. Hence an experiment was set out as described in section 
3.2.2.3.2. Wild type PEPV was passaged 5 times in 25cm
3
 sterile tissue culture flasks. 
The first 25cm
3
 flask was infected with 3X10
5
 pfu of PEPV. After 3 days the virus 
lysate was used to infect another flask. This was repeated until the virus had been 
passaged 5 times. 
 
Once all the virus was harvested from the infected flasks, virus from each time point 
was diluted 10 fold and 100 fold, i.e. 3 different viral dilutions. A total of 54 eggs were 
infected, three eggs for each dilution, 3 dilutions and 6 passages including P0. 4 days 
post inoculation infected CAMs were spread onto petri dishes and the pocks were 
counted. The virus titre was calculated for each passage and a growth curve was 




Figure 3.4. Growth curve to examine if wtPEPV adaptes to growth in RK-13 cells 
upon multiple passages. 2 flasks of RK-13 cells were infected with 3x10
5
 pfu of PEPV. 
After infection, a flask was frozen. The second flask was left for 3 days, then frozen (P1), 
P1 was freeze/thawed 3 times, then used to infect another flask of RK-13 cells. After 3 
days this flask was freeze/thawed 3 times (P2) and the procedure repeated until the virus 
had been passaged 5 times. Virus from all the flasks was titrated on chick CAMs and 
expressed as pfu/ml. 
 
The data (Figure 3.4) shows a dramatic decrease in viral titre after the first passage 
(from 8500pfu/ml to 750pfu/ml). No virus was seen after the second passage. This 
indicated that PEPV was unable to adapt to grow in RK-13 cells at the titres which were 
being used; 
 
(An observation: there is 8x more virus in the second growth curve than the first at P0 








Stannard and her group tested whether PEPV would recognize late promoter sequences 
derived from VACV (Stannard et al., 1998). A plasmid containing the reporter gene β-
gal under the control of the VACV late promoter, P11, was transfected into RK-13 cells 
infected with PEPV. No expression was detected. Expression was, however, detected in 
other cells, showing that PEPV does indeed recognize the P11 promoter (Stannard et al., 
1998). This experiment further showed that RK-13 cells are not permissive for the 
growth of PEPV and that the block occurs before DNA replication as replication takes 
place before late gene expression can take place. The transcriptase responsible for 
recognizing the late promoter is synthesized during the intermediate phase of the 
Poxvirus replication cycle (Moss, 2007). No late gene expression took place due to the 
fact that no transcriptase was present to recognize the P11 promoter and hence 
transcribe the β-Gal gene (Stannard et al., 1998). This may indicate that after PEPV 
enters RK-13 cells, replication is blocked during or before the intermediate phase (Moss, 
2007). 
 
One can presume that most of the PEPV was capable of infecting and entering the host 
cells, as studies have shown that the binding and entry of Poxviruses into mammalian 
cells is an efficient process, and restriction only occurs after the virus has entered the 
cell (McFadden, 2005). These results show that after PEPV enters the host cell and 
becomes uncoated, the virus is unable to complete its replication cycle and hence unable 
to produce infectious viral progeny. The virus detected on Day 1 was probably the 
PEPV that remained on the host cell surface, before it under-went uncoating. This 
growth curve experiment showed that RK-13 cells are non-permissive for PEPV growth, 
which was important to establish before using VACV K1L host range gene as a selective 
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marker for recombinant virus construction, to ensure that the only virus which grows in 
RK-13 cells is that with the VACV K1L gene present. 
 
During the project an attempt was made to passage the wtPEPV in RK-13 cells, in order 
to determine if PEPV is capable of adapting itself to grow in RK-13 cells (see section 
3.3.2). This was the first attempt to passage PEPV in a known cell line. During the 
process, the viral load reduced dramatically upon the first passage and no virus was 
detected after the second passage. Despite 3X10
5
 pfu of PEPV being used to infect the 
cells, none of it was capable of adapting to RK13 cells. One can argue that an increase 
in concentration of PEPV can raise the possibility of finding mutated PEPV to adapt to 
RK13 cells. However, our aim was not to adapt the virus to grow in RK-13 cells, but 
rather to show that the virus does not adapt to grow in RK-13 cells when used at the 
same titre as that used for infection and transfection experiments (Chapter 5). Previous 
work done by Stannard et al (1998) and tissue culture work done in this project showed 
that PEPV alone was unable to advance its replication cycle to the intermediate phase of 
the replication cycle in RK-13 cells. It is not known whether all early phase proteins are 
expressed. However it is unlikely for PEPV to adapt to growth in RK13 cells with the 
block in its replication cycle occurring at such an early stage.  
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The long term goal of this project is to develop a recombinant PEPV for use as a 
vaccine. The noninfectious nature of poxvirus DNA and its large genome prevent one 
from direct manipulation of the viral DNA. However, the viral DNA can be manipulated 
by means of homologous recombination between the viral genome and a transfer vector 
(Wyatt et al., 1998; Panicali et al., 1982; Hahn et al., 2000).  
 
Insertion of foreign DNA into poxviruses involves the construction of a recombinant 
plasmid containing the foreign DNA/genes, flanked by poxviruses genomic sequences. 
This transfer vector is introduced into poxvirus infected cells and recombination takes 
place between the flanking poxvirus sequences and the homologous sequences of the 
poxvirus genome during replication within the cells (see Figure 4.1). Hence the foreign 
gene inserts within the transfer vector will subsequently be packaged into the infectious 
virus (Panicali et al., 1982).  
 
Insertion of the foreign gene into the poxvirus can be lethal to the virus if the foreign 
gene is inserted into an essential region of the genome; therefore it is important to allow 
the recombination to take place within a nonessential region. Many genes are critical for 
replication and completion of the virus life cycle. However, certain genes are not 
essential to the virus and are suitable sites for the insertion of foreign genes. One of the 
most commonly used nonessential genes in the construction of recombinant viruses is 
the thymidine kinase (TK) gene. The function of thymidine kinase is to phosphorylate 
thymidine, which is important for synthesizing DNA and thereby plays an important 
role in cell division, however such kinases exist in most living cells, and TK is not 
essential for the growth of poxviruses. It has been widely used as the locus of insertion 
64 
for foreign genes (Kit, 1985; Hahn et al., 2000; Perkus et al., 1989). It has been used in 
the construction of recombinant swinepox viruses expressing classical swine fever virus 
protein (Hahn et al., 2000). It also has been used in the construction of a recombinant 
Fowlpox virus, expressing the protein of bovine viral diarrhea virus (Elahi et al., 1999). 
Homologous recombination is a rare event and can be influenced by the length of the 
homologous flanking sequence (Yao et al., 2001). Sequences of at least 50bp are 
required for homologous recombination and the longer the flanking sequences, the 
greater the probability of recombination (Yao et al., 2001).  
 
For the construction of an ideal transfer vector, there are two other elements that would 
optimize the construction of a recombinant poxvirus, a selective marker gene and a 
reporter gene. The purpose of the positive selection marker is to enable one to identify 
and select the recombinant virus from the rest of the non-recombinants.  
 
The presence of a reporter gene such as β-Galactosidase, β-glucuronidase or luciferase 
allows one to visualize plaques produced by recombinant virus. In the construction of a 
transfer vector, the reporter gene is required to be under the control of a poxvirus 
promoter that can be recognized by the poxvirus. During the selection of recombinant 
virus, the infected and transfected cells are incubated with the colourless substrate of the 
reporter gene product. The expressed reporter gene will subsequently convert its 
colourless substrate and into a coloured product. This enables one to identify cells 
which are expressing the reporter gene. The reporter gene used in this project was β-
glucuronidase (GUS), an enzyme isolated from the bacterium Escherichia coli. This 
enzyme was first identified by Jefferson (1989); since then, it has become one of the 
most frequently used reporter genes. For the detection of transfected cells or 
recombinant virus in a GUS reporter gene system, the infected and transfected cells are 
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incubated with the colourless substrate, 5-bromo-4-chloro-3-indolyl glucuronide (X-
Gluc). Cells expressing GUS enzyme will convert the substrate into a blue product and 
the cells will appear blue. 
 
The rest of the elements for constructing an ideal transfer vector include a pair of direct 
repeat sequences flanking these two foreign genes, which, ultimately could remove the 
selective marker and reporter genes (this is to ensure safety of the final recombinant 
virus), and lastly restriction enzyme sites for the future insertion of vaccine antigen 
genes, which are located outside of the direct repeats, so that the required gene is not 
deleted from the final recombinant virus. The restriction enzyme sites need to be located 
downstream of a poxvirus promoter so that transcription of the vaccine antigen is under 
the control of a poxvirus promoter (see Figure 4.1). 
 
In this study, a transfer vector (pNCH-3) was constructed based on the backbone of the 
pLW51 plasmid (see Appendix I for plasmid map). The plasmid vector pLW51 (Wang et 
al., 2004) contains a β-lactamase gene (amp
R
) which confers ampicillin resistance amp
R
, 
which acts as a selection marker for transformation in bacteria. The vector also contains 
a β-glucuronidase (GUS) gene under the control of a VACV p11 promoter. The function 
of this reporter gene was described above and its presence will allows one to detect cells 
which have been both infected with poxvirus and transfected with plasmid. This is 
because the p11 promoter is a poxvirus late promoter, which can only be recognized by 
poxvirus transcription factors. However, pLW51 does not possess a selective marker for 
the selection of recombinant PEPV from the non recombinants, hence in this study the 
Vaccinia virus K1L host range gene was cloned into the pLW51 vector to determine if it 
could be used for selection of recombinant virus. The previous chapter (section 3.1) 
describes the use of K1L as a selection marker. Once homologous recombination takes 
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place, recombinant virus with VACV K1L will grow in RK-13 cells whereas the wild-
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Figure 4.1. Schematic diagram (not to scale) of the construction of recombinant 
Poxvirus (adaptation from Byrd et al., 2008). Cells are infected with virus, then 
transfected with a transfer vector. Homologous recombination takes place in the 
cytoplasm of the cell. 
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pLW51 also contains multiple cloning sites for future construction of a vaccine vector 
situated downstream of two VACV promoters, PsynII promoter and pmH5 promoter. 
One can then decide to either clone downstream of the PsynII promoter for strong 
expression or downstream of the pmH5 promoter for weaker expression. As previously 
discussed, a pair of direct repeats is essential to ensure the safety of the vector. In 
pLW51, a pair of direct repeat sequences are located on each side of GUS, the one 
repeat being just upstream of the p11 promoter, so that ultimately, GUS can be removed 
from the desired reombinant pox virion genome. 
 
The final transfer vector construct (pNCH-3) was designed to contain a multiple cloning 
site downstream of the pmH5 promoter, a GUS reporter gene, a VACV K1L gene, a pair 
of direct repeat sequence flanking the GUS and K1L gene and lastly PEPV TK 
sequences flanking the cassette. Figure 4.2 shows a schematic diagram of the transfer 
vector used in the construction of recombinant PEPV and Figure 4.3A-D shows 
schematic diagrams of the cloning procedures followed for the construction of the 
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Figure.4.2. Schematic diagram (not to scale) of the transfer vector used in the 
construction of recombinant PEPV. Foreign genes were inserted between the PEPV 
TK flanking sequences (brown). The VACV K1L selection gene (red) and E.Coli GUS 
reporter genes (dark blue) were flanked by direct repeat (light blue). Outside of the 
direct repeat and within the TK flanks are 2 promoters, psynII and pmH5 (green arrows). 
A single Sma I restriction enzyme site is located immediately downstream of the pmH5 
promoter. 
 
4.2 Materials and Methods 
 
Figure 4.3 shows the procedure employed in the construction of the transfer vector 
pNCH-3. The first step was PCR amplification of the PEPV flanking sequences and the 
VACV K1L gene from PEPV and VACV genomic DNA respectively. In this study, 
amplified PCR products were first cloned into pGEM T Easy vector (Appendix I), 
thereafter several cloning procedures were performed before the final transfer vector 
pNCH-3 was constructed. 
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Figure.4.3A. Schematic diagram (not to scale) of the first part of the cloning 
procedures followed in the construction of pNCH-3 transfer vector. VACV K1L host 
range gene, PEPV flanking sequences, TK left and TK right, were amplified from 
VACV and PEPV genome respectively. The amplified DNA fragments were separately 











Hind III Pst I Sma I Eco RI 
PCR amplification 
pGEM T Easy 
Vector 
VACV K1L TK Left flank TK Right flank 
pGEM K1L 
K1L 




Sma I Eco RI 
pGEM TKleft 
TK Left 





















































Figure.4.3B. Schematic diagram (not to scale) of the second part of the cloning 
procedures followed in the construction of pNCH-3 transfer vector. VACV K1L 
gene was extracted as a Bss HII fragment from pGEM K1L (Figure 4.3A) and cloned 
into the Bss HII site of pLW51. 
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Figure.4.3C. Schematic diagram (not to scale) of the third part of the cloning 
procedures followed in the construction of pNCH-3 transfer vector. Gel extracted 
and purified PEPV TK flanks were cloned into pUC21 vector sequentially. The TK left 
flank was first cloned into the Hind III and Pst I cloning sites of pUC21. The TK right 
flank was then cloned into the recombinant pUC21TKleft plasmid into the Sma I and 
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Figure.4.3D. Schematic diagram (not to scale) of the last part of the cloning 
procedures followed in the construction of pNCH-3 transfer vector. pLW51/K1L 
plasmid was digested with Cla I, BamoHI and Eco RI, producing a 3.8kb fragment 
comprised of many of the essential elements for the transfer vector. This fragment was 
first blunted-ended then cloned into pUC21tkL+R vector into the Sma I site. Eco RI was 
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4.2.1 PEPV and VACV DNA Extraction  
 
PEPV and VACV DNA was required as template in the PCR reactions for the generation 
of PCR products which were to be used in the construction of a transfer vector, required 
for the generation of recombinant PEPV (see Figure 4.3A). 
 
Poxvirus DNA extraction was performed as described by Sambrook (1989) with a 
modification to the lysis buffer. The virions were lysed using a lysis buffer of 10% Na-
N-Lauryl Sarcosinate, 54% (w/v) sucrose solution and 1M Tris-HCl (pH 7.8). The 
solution was autoclaved and stored at 4
o
C. β-mercaptoethanol was added to the lysis 
buffer to a final concentration of 200mM prior to DNA extraction.  
 
An equal volume of lysis buffer was added to the viral suspension and mixed via 
inversion. The mixture was then incubated at room temperature for 15 minutes to allow 
the lysis buffer to lyse the viral membrane completely. Proteinase K (final concentration 
was 2mg/ml) was added, followed by RNase A (final concentration was 100µg/ml). 
Lysates were incubated at 56
o
C for 1.5 hours. The purpose of the step was to denature 
and degrade all the proteins present in the solution including nucleases. This is to 
prevent the nucleases from degrading the DNA. RNase A was used to degrade the RNA. 
 
After lysis and Proteinase K digestion an equal volume of Phenol solution was added to 
the contents and mixed via inversion. Mixed solutions were then centrifuged at 
13000rpm for 5 minutes at room temperature, in an Eppendorf 5417C benchtop 
centrifuge. Two layers were seen after centrifugation. The top aqueous layer, containing 
viral DNA, was carefully transferred into a sterile 1.5ml microfuge tube and the bottom 
layer, containing phenol, lipid and protein, was discarded. This procedure was repeated 
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to ensure the removal of all impurities. Next, an equal volume of chloroform:isoamyl 
alcohol (24:1) was added to the recovered viral DNA. Mixtures were mixed via 
inversion and subjected to centrifugation at 13000rpm (Gene Company, Eppendorf 
Centrifuge 5417C) for 5 minutes at room temperature. Again two layers were seen after 
centrifugation. The top layer, consisting of the purified DNA, was transferred to a new 
sterile 1.5ml microfuge tube. This step was repeated to ensure all traces of phenol were 
removed. One-tenth of the final volume of ice cold 3M sodium acetate was added to the 
DNA followed by 2.5 times the volume of ice cold 95% ethanol. This was to precipitate 
the DNA. The solution was first mixed by inversion and then incubated at -80
o
C for 1 




The microfuge tubes were centrifuged at 13000rpm for 20 minutes at 4
o
C (Gene 
company, Eppendorf Centrifuge 5415R). This procedure was to pellet the precipitated 
DNA. After centrifugation, the supernatants were removed and DNA pellets were 
washed with 200µl ice-cold 70% ethanol and centrifuged again. The ethanol was 
carefully removed to avoid the DNA pellet being discarded. DNA pellets were 
resuspended in 50µl Tris-EDTA buffer (pH 7.5) or HPLC water and stored at -20
o
C. 
The DNA concentration was determined by nanodrop (NanoDrop
®
 Spectrophotometer 
ND-1000) and the DNA integrity was checked by standard agarose gel electrophoresis. 
 
4.2.2 Polymerase Chain Reaction (PCR)  
 
PCR was performed for the initial steps in the construction of the transfer vector (see 
Figure 4.3A). There were three primer sets designed for polymerase chain reaction 
(PCR) amplification of the required DNA fragments (shown in Table 4.1).  
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Table 4.1. Primers used to amplify TK left, TK right and VACV K1L fragments 
Primers Orientation Usage Sequence 
TK Left Forward Amplify TK left fragment 
5’ AAGCTTATGGCTTCCGGAAGTATCCATGTT 3’ 
  
TK Left Reverse Amplify TK left fragment 
5’ CTGCAGACTATATCTAGGAAGAATTGACCTTC 3’ 
 
TK Right Forward Amplify TK right fragment 
5’ CCCGGGAGAATTTAGTGAATCTATGGCTAA 3’ 
 
TK Right Reverse Amplify TK right fragment 




Forward Amplify VACV K1L 
fragment 




Reverse Amplify VACV K1L 
fragment 










Figure.4.4. Sequence of PEPV Thymidine Kinase gene. The red underlined 
sequences indicate the position of primer sequences used to amplify a fragment from the 
left end (TKleft). The dark blue underlined sequence indicates the primer sequence used 
to amplify a fragment from the right end (TKright). 
 
Two primer sets were designed, as described in section 4.2.2.1, based on the sequence 
from the thymidine kinase (TK) gene of PEPV. This gene sequence was determined by 
Olivia Carulei, Division of Medical Virology, Department of Clinical Laboratory 
Sciences, UCT (sequence shown in Figure 4.4). Primer sets were designed to amplify 




































Figure 4.5. Sequence of VACV K1L gene. The red underlined sequences indicate the 
primer sequences used to amplify VACV K1L together with its promoter element.  
 
The DNA sequence of a Vaccinia virus host range gene, K1L, sequence was retrieved 
from Genbank (Accession No. NC_006998, see Figure 4.5). A primer set was designed 
such that both the VACV K1L gene and its promoter would be amplified by PCR. A Bss 
HII restriction enzyme site was included at the 5’ end of each primer (see Table 4.1) so 

























4.2.2.1 Primer Design 
 
When designing PCR primers the following two factors are taken into consideration: 
1) The melting temperature of the primers (Tm). It is essential that the melting 
temperature of the forward and the reverse primers are approximately the same. This 
is to ensure that both the forward and reverse primers can anneal to the template 
DNA at the same temperature. The PCR reaction will not take place if both primers 
do not anneal at the same time. The Tm was determined using the following formula: 
Tm = 4 x (no. of Guanosine and Cytosine) + 2 x (no. of Adenine and Thymine) 
 
2) The base composition of the primer. During the primer designing process, it is 
essential to consider the specificity of the primers, i.e. does the primer only anneal to 
the template DNA at the desired location. There is a 25% probability for each base in 
a primer to bind randomly to the template DNA. Therefore the probability of a 
designed primer, with X number of bases, to bind randomly to the template DNA is 
equal to (25%)
 x
. Thus the longer the primer, the lower the possibility of the primer 
binding nonspecifically. It is also important to ensure that the primer pairs do not 
have palindromic sequences which could bind to one another and that the two 
primers do not have reverse complementary sequences which would allow the 
primers to bind to one another. 
 
Primers were synthesized by UCT synthetic DNA laboratory, using a Beckman Oligo 




4.2.2.2 PCR Amplification  
 
PCR master mix reagents were supplied by Bioline, United Kingdom. The reagents 
consisted of PCR buffer with MgCl2, dNTPs and Taq DNA polymerase for the PCR 
reaction.  
 
PCR amplification was performed as described by Sambrook (1989). The reaction 
conditions were set as follows: 
PEPV DNA was first denatured at 95
o
C for 10 minutes prior to the main PCR cycle. 
This was to ensure all double stranded DNA was denatured and formed single 
stranded DNA. In the main PCR reaction cycle, DNA was first denatured at 95
o
C for 
30 seconds; then primer annealing to the single stranded template was allowed to 
take place at 5
o
C below the melting temperature of the primers, for 30 seconds; and 
thirdly, extension of the DNA from the primers took place at 72
o
C, the length of time 
for extension depending on the length of DNA to be amplified. 1kb of DNA fragment 
required 1 minute of extension time. For this study, in total, 30 cycles of denaturation, 
annealing and extension were performed. Finally, to ensure complete extension of 
DNA, the PCR reaction was left at 72
o




Amplified fragments were detected by agarose gel electrophoresis, using 1% agarose 
gels.  
 
4.2.3 DNA Purification 
 
PCR products and Plasmid DNA were purified before being cloned. A specific volume 
of amplified DNA was measured. A half volume of phenol was added to the PCR 
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products, the contents were vortexed, a half volume of chloroform:isoamylalcohol (24:1) 
was added, the mixture was vortexed again and then centrifuged for 2 minutes at 
13000rpm (Gene Company, Eppendorf Centrifuge 5417C), at room temperature. Two 
layers were seen, a bottom layer consisting of protein trapped by phenol and a top layer 
consisting of the DNA products, which was transferred to a sterile 1.5ml microfuge tube. 
This procedure was repeated for 1~2 times to ensure the DNA was pure. An equal 
volume of chloroform:isoamylalcohol (24:1) was added to the recovered solution. It 
was then vortexed and centrifuged at 13000rpm (Gene Company, Eppendorf Centrifuge 
5417C) for 2 minutes at room temperature. Again two layers were seen, the bottom 
layer consisting of the carried over phenol solution, trapped by 
chloroform:isoamylalcohol, and the top layer consisting of the DNA. DNA was 
transferred to a sterile 1.5ml microfuge tube. This procedure was repeated 1~2 times to 
ensure purity of the DNA. One tenth volume of ice cold 3M sodium acetate was added 
to the solution, followed by 2.5 volume of 100% ethanol. This was to precipitate the 
DNA. The solution was first mixed by inversion and then incubated at -80
o
C for 1 hour 
or at -20
o
C over night. Products were centrifuged at 13000rpm (Gene Company, 
Eppendorf Centrifuge 5415R) for 15~30 minutes at 4
o
C in order to pellet the DNA. 
Supernatants were discarded and DNA pellets were washed with ice cold 70% ethanol 
and finally resuspended in 50µl HPLC H2O.  
 
The DNA concentration of the purified DNA products was determined by nanodrop 
(NanoDrop
®








The next steps in the construction of the transfer vector involved several cloning 
procedures, which required preparation of competent cells, several ligation reactions 
and transformations and selection of positive recombinant plasmids, as described below. 
 
4.2.4.1 Preparation of Competent cells for Transformation 
 
Competent cells were prepared according to the method of Chung (1988) 
immediately before transformation; this was to ensure maximum competency of the 
cells.  
 
DH5α cells were inoculated into 5ml of 2x Yeast-Tryptone (YT) broth (1.6% 
Tryptone, 1.0% yeast extract, 0.5% NaCl, pH 7.0), in a sterile standard container, and 
incubated at 37
o
C overnight with shaking.  
 
The overnight culture was diluted 100x in 50ml prewarmed 2YT broth in a 500ml 
flask. The diluted culture was then placed on a shaker and incubated at 37
o
C for 
2~2.5 hours. This was to allow the growth of the culture to reach early log phase. 
Early log phase can be measured by reading the absorbance of the culture at 600nm 
wavelength, using a spectrophotometer. A culture in early log phase will show an 
absorbance of 0.2 - 0.4 at OD600.  
 
The bacterial cells in early log phase were pelleted by centrifugation, at 5000rpm for 
5 minutes at 4
o
C. Centrifuge tubes were precooled at 4
o
C prior to centrifugation. The 
supernatant fluid was discarded and the bacterial pellets were resuspended in 1/10  
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volume of cold TSB solution [1.6% Peptone, 1.0% yeast extract, 0.5% NaCl, 10% 
PEG (MW:3350-4000), 5% DMSO, 10mM MgCl2, 10mM MgSO4] and 15% (v/v) 
glycerol.  
 
4.2.4.2 Transformation and Competency Testing 
 
The competency of the cells was determined in every transformation experiment. 
This was to ensure the cells were competent enough for transformation. Plasmid 
DNA with known concentration was added to 100µl of competent cells and left on ice 
for 30-60 minutes. Cells were heat shocked at 42
o
C for 2 minutes; this was to 
enhance the transformation efficiency. 0.9ml of 2YT broth was added to the 
competent cells and they were incubated at 37
o
C for 30 - 60 minutes. This was to 
provide an antibiotic-free environment for the bacteria to express the antibiotic 
resistance gene. 100µl of the contents were plated on Luria agar containing 10mg/ml 
ampicillin and incubated at 37
o
C overnight. The colonies were counted and the 
competency of the cells determined as the number of colonies / µg of vector. 
  
4.2.4.3 Cloning of PCR products into pGEM T Easy vector 
 
Standard DNA cloning entails the ligation of DNA products that have been digested 
with restricted enzymes which result in either an overhang of specific base sequences 
or blunt-ends, which can ligate to a vector that has been digested to have 
complementary ends. However, Taq DNA polymerase, used to generate PCR 
products, lacks 3’ to 5’ exnuclease activity which is associated with most DNA 
polymerases. This means synthesized PCR product often have a single template 
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independent nucleotide at the 3’end of the DNA strand (Newton et al., 1998), thus 
preventing one from cloning the PCR products into standard circular plasmid vectors 
such as pUC21 and pLW51. Amplified fragments were first cloned into pGEM T 
Easy (supplied by Promega, United States), a vector designed for the cloning of PCR 
amplified products which have poly-A tails. Following cloning into pGEM T Easy the 
desired fragment can easily be purified after appropriate restriction enzyme digestion. 
 
Reagents were added as described in the pGEM-T Easy vector user manual. Vector 
and control DNA, supplied by Promega, United States, were first centrifuged to 
collect the DNA. The following equation was used to determine the amount of vector 
and insert DNA to use in ligation reactions: 
ng of insert = {(ng of vector x kb size of insert) / (kb size of vector)} x ratio of insert 
to vector 
 
Ligation reactions were carried out according to the manufacturer’s instructions 
(Promega, Madison, Wisconsin, United States) and then used to transform competent 
E. Coli DH5α cells (sections 4.2.4.1 and 4.2.4.2). 
 
During the cloning procedure, competent cells were transformed with the original 
plasmid DNA in order to calculate the competency of the cells. In addition, cells were 
transformed with ligated plasmid to select for recombinant plasmid. The vectors 
pGEM T Easy and pUC21 have a lacZ gene thereby allowing for blue-white selection. 
These vectors were originally designed in such a way that the multiple cloning sites 
were situated within the β-galactosidase gene. Cloning of foreign DNA into the 
multiple cloning sites would lead to disruption of the β-galactosidase gene; hence 
when one plated out on selective media containing IPTG and X-gal, no β-
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galactosidase would be available to utilize X-gal. Therefore E. Coli transformed with 
the vector containing an insert would produce white colonies (Sambrook et al., 1989). 
 
Transformed competent cells were plated onto selective medium containing 
ampicillin (10mg/ml), IPTG (5x10
-5
 M) and X-gal (5mg/100ml). Media with 
ampicillin allowed for selective growth of cells containing a plasmid coding for 
ampicillin resistance. DH5α cells alone were unable to grow in the presence of 
ampicillin, whereas the vectors used in the cloning procedures all contained an 
ampicillin resistance gene. Therefore during the transformation process, if DH5α is 
transformed by a plasmid, such a cell would confer resistance to ampicillin. IPTG is 
an inducer for β-galactosidase, it induces transcription of the β-galactosidase gene 
from the vectors. Expressed β-galactosidase utilizes X-gal present in the selective 
media and turns the bacterial colony blue as mentioned above. Hence to select for the 
recombinant plasmid, one would select the white colonies.  
 
4.2.4.4 Plasmid Isolation (small-scale preparation) 
 
The alkaline lysis method for minipreparations of plasmid DNA was followed, as 
described in Sambrook (1989), in order to identify colonies with the desired 
recombinant plasmid. 
 
Single colonies were plated onto a gridded plate and added to sterile tubes with 5ml 
sterile 2YT medium. The plates and liquid cultures were incubated at 37
o
C overnight; 
the liquid cultures being placed under constant agitation.  
 
The gridded plate was kept as a reference plate so that each possible recombinant 
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colony could be assigned a defined number, and once the desired recombinant 
plasmid was identified by analyzing the extracted DNA, one could then trace back to 
the original colonies and mass produce the identified colony for further 
experimentation. 
 
Two millilitres of the cell suspension was microcentrifuged for 2 minutes at 
13200rpm, (Gene company, Eppendorf Centrifuge 5417C) at room temperature to 
pellet the cells. The supernatants were discarded. Another 2ml of the overnight 
culture was added to the pellet, microcentrifuged for 2 minutes at 13200rpm (Gene 
Company, Eppendorf Centrifuge 5417C) and the supernatant fluids were discarded. 
This was to collect as many cells as possible. The pellets were resuspended in 200µl 
of ice cold resuspension solution [50mM glucose, 25mM Tris-HCl (pH 8.0), 10mM 
EDTA (pH 8.0)] and left at room temperature for 10 minutes. 200µl of lysis solution 
(1% SDS, 0.2M NaOH), which acts as a detergent, was added to each tube in order to 
lyse the cells. The solutions were mixed by inversion 7~8 times and placed on ice for 
10 minutes. 300µl of neutralization solution (5M potassium acetate, pH 4.8) was 
added to each tube, mixed via inversion 7-8 times, and left on ice for another 10 
minutes. The tubes were centrifuged at 13200rpm (Gene Company, Eppendorf 
Centrifuge 5417C) for 5 minutes at room temperature. This was to pellet all unwanted 
debris. 
 
The supernatant fluids were transferred to sterile 1.5ml microfuge tubes and 600µl 
isopropanol was added. The contents were mixed via inversion and placed at room 
temperature for 2 minutes. Plasmid DNA was pelleted by centrifuging the tube at 
13200rpm (Gene Company, Eppendorf Centrifuge 5417C) for 10 minutes at room 
temperature. The supernatants were carefully removed, the pellets were washed with 
85 
200µl ice cold 70% ethanol, all ethanol was removed, the pellets were dried and 
resuspended in 50µl HPLC H2O or TE buffer. Plasmid DNA was stored at 4
o





4.2.4.5 Plasmid Isolation (large-scale preparation) 
 
Once the desired recombinant plasmids were identified, large-scale (maxi) 
preparations were made of the recombinants.  The kit used for Plasmid Isolation 
(Maxi) was supplied by QIAgen, Germany, and the procedure was followed 
according to the manufacturer’s instruction provided by the supplier. 
 
A colony was grown in 100ml Luria Broth in a 1 litre flask. The culture was 
incubated overnight, on a shaker at 37
o
C. Cultures were centrifuged at 4000rpm for 5 
minutes at 4
o
C. Supernatants were discarded and 2ml of suspension buffer with 
RNase was added to resuspend the pellet. 4ml of lysis buffer was added, the 
suspension was well mixed by inverting the tube 6-8 times and the tube was placed 
on the bench for 2-3 minutes to allow the cells to be lysed. 4ml of pre-cooled 
neutralization buffer was added to the suspension and well mixed by inversion (6-8 
times). At this point a homogenous suspension appeared, which was incubated on ice 
for 5 minutes. 
 
A piece of filter paper was placed in a funnel; the funnel was inserted into a sterile 
container. The filter paper was first equilibrated with equilibration buffer before the 
addition of lysate to the filter. Flow through (containing the plasmid DNA) was 
collected in the sterile container while the lysed cells were left on the filter. The 
filtering procedure was repeated in order to ensure the purity of the flow through. 
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A sealing ring provided by the kit was mounted to the column and the column was 
mounted onto a sterile 50ml tube. The column was then equilibrated with 2.5ml of 
equilibration buffer. Flow through was discarded and the cleared lysate, purified by 
filtration, was added to the equilibrated column. While the lysate flowed through the 
column, DNA was trapped within the column. This procedure was repeated to 
increase the amount of DNA collected on the column. 
 
DNA on the column was washed with 5ml of washing buffer. Buffer was allowed to 
filter through the column. The process was repeated to ensure the purity of the DNA. 
DNA was eluted from the column by adding pre-warmed (50
o
C) elution buffer to the 
column. The eluted DNA was aliquotted (900ul per tube) into sterile 1.5ml microfuge 
tubes and 600µl of Isopropanol was added to each tube to precipitate the DNA. The 
DNA was centrifuged at 13200rpm for 30 minutes at 4
o
C. The supernatant was 
discarded and the DNA pellet was washed with 600µl ice cold 70% ethanol. The 
pellet in each tube was resuspended in 50µl of HPLC water. All resuspended DNA 
was then transferred into one sterile 1.5ml tube.  
 
The DNA concentration was determined by NanoDrop
®
, Spectrophotometer ND-
1000. DNA was then subjected to standard agarose gel electrophoresis to confirm its 
integrity. The plasmid identity was confirmed by restriction enzyme digestion and 
agarose gel electrophoresis. 
 
Endotoxin free plasmid was prepared as described above with the addition of 




4.2.4.6 Restriction Enzyme Digestion 
 
Restriction enzyme digestion was used during the cloning procedure to cleave the 
desired fragments from recombinant plasmids, to linearize vectors and to confirm the 
identity of recombinant plasmids. 
 
Restriction endonuclease enzymes were supplied by Fermentas, United States. 
Instructions were followed as described in the manual provided by the suppliers. All 
digestions were incubated at the temperature indicated in the manual, for 2-2.5 hours, 
to ensure complete DNA digestion. Digested DNA was examined by standard agarose 
gel electrophoresis, as described below. 
 
4.2.4.7 Agarose Gel Electrophoresis 
 
The method for agarose gel electrophoresis was followed as described by Sambrook 
(1989). The purpose of agarose gel electrophoresis was to separate nucleic acids 
according to the sizes of the fragments. The apparatus used for electrophoresis 
consists of two buffer tanks containing positive and negative electrodes respectively, 
which are connected to a voltage supply. The gel lies between the two tanks. Nucleic 
acid fragments migrate through the agarose gel matrix when exposed to an electrical 
current. Because the net charge of DNA is negative, DNA fragments will migrate 
towards the positive electrode. Smaller fragment will move faster through an agarose 
matrix than larger ones; hence the separation of fragments according to size. 
 
All gels were made up in 1xTris-Borate-EDTA electrophoresis buffer (90mM Tris, 
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90mM Boric acid and 2mM EDTA). After the agarose gel had been placed in the 
electrophoresis apparatus, 1x TBE was added to cover the agarose gel. This buffer 
served to conduct the voltage between the positive and negative electrodes during 
electrophoresis. The percentage agarose was adjusted according to the size of the 
DNA fragments to be separated. A high percentage of agarose results in a smaller 
matrix within the gel, and is therefore more suitable for the separation of small DNA 
fragments.  
 
Ethidium bromide (EtBr) was used to detect DNA fragments on agarose gels. It is a 
DNA interchalating agent which fluoresces under UV light. EtBr was either added to 
the agarose gel before the gel polymerized, at a final concentration of 0.1mg 
EtBr/100ml of agarose, or, after gel electrophoresis in which case it was added to a 
staining buffer at a final concentration of 0.1mg/100ml. DNA fragments were 
visualized on a transilluminator UVP Box. 
 
The actual sizes of the DNA fragments could be determined by comparing the 
fragment positions to those of molecular weight markers with known sizes (Appendix 
II).  
 
4.2.4.8 Purification of DNA Fragments by Gel Extraction 
 
During transfer vector construction, one of the procedures was to clone a section of 
one plasmid into another plasmid. To prevent vector religation or cloning of the 
wrong fragment, and hence a low yield of desired recombinant plasmid, it was 
essential to gel extract the fragment of interest. 
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Restriction endonuclease digestion was carried out as described in section 4.2.4.6. 
This was to cleave the desired DNA fragment from a plasmid. Digested DNA was 
subjected to standard agarose gel electrophoresis to separate the desired fragment 
from the vector. Once electrophoresis had taken place the gel was removed from the 
apparatus and the band consisting of the desired DNA fragment was cut out from the 
gel and placed in a sterile 2ml microfuge tube. 
 
A gel extraction kit was supplied by QIAgen, and the following procedure was 
followed from the user manual, supplied by QIAgen.  
 
Buffer QG was added to the 2ml microfuge tube at a ratio of 1mg gel: 3µl buffer QG. 
This was then incubated at 50
o
C until the gel had dissolved. Isopropanol was added to 
the mix at the ratio of 1mg gel: 1µl isopropanol. The solution was first mixed via 
inversion for 6~8 times and then transferred to a spin column. The column was 
centrifuged at 13200rpm for 1 minute; this was to allow the DNA to bind to the 
column and the debris to pass through the column. 750µl of buffer PE with ethanol 
was added to the column, and the column was again subjected to centrifugation at 
13000rpm for 1 minute. Buffer PQ served to wash the DNA that was bound to the 
column. Flow through was discarded and to ensure all residue in the column was 
removed, the column was centrifuged again at 13000rpm for 1 minute. 50µl of HPLC 
water was added to the column to elute the DNA, and the column was centrifuged at 
13000rpm for 1 minute. 
 
4.2.4.9 Vector Preparation 
 
Vectors were first linearized with the desired restriction endonuclease(s). Digested 
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vectors were subjected to DNA purification as described in section 4.2.3. This was to 
remove the enzymes and buffers in the solution. After purification, to prevent vector 
religation, the linearized vector was treated with calf intestinal phosphatase (CIP) 
prior to ligation with the desired DNA fragment. 
 
4.2.4.9.1 Treatment of Digested Vector with Calf Intestinal Phosphatase (CIP) 
 
CIP enzyme and buffer were supplied by Sigma Aldrich, United State. Experiments 
were carried out as stipulated in the user manual.  
 
1U of CIP enzyme was used to treat 1 pmol of DNA. To calculate the amount of 
DNA to use, the following equation was used: 
DNA (pmol) = (2X10
6
 x µg of plasmid) / (bp of plasmid x 660) (Sambrook et al., 
1989) 
Reagents were added as stipulated in the user manual. The solution was incubated 
at 37
o
C for 1 hour. DNA subjected to CIP was purified as described in section 4.2.3 
prior to the ligation step, so as to remove the CIP enzyme and buffer.  
 
4.2.4.10 Ligation and Transformation 
 
After the vector had been treated with CIP and purified, it was ready to be ligated 
with the desired DNA fragment. T4 DNA ligase and its buffer were supplied by 
Roche, Germany; and ligation was carried out as instructed in the user manual. Ratios 





The following equation was used when determining the amounts of insert and vector 
to use.  
 
ng of insert =  
(ng of vector x kb size of insert) / (kb size of vector) x ratio of insert to vector 
 


























ng amount of 
insert and vector 
0 0 2 1 Add up to 20 
Experiment 2 
Ration 10:1 
ng amount of 
insert and vector 
0 0 2 1 Add up to 20 
Contamination 
control 
0 0 0 0 2 1 Add up to 20 
Competency 
test 
0 0 0 100ng 2 1 Add up to 20 
0 0 0 10ng 2 1 Add up to 20 
0 0 0 1ng 2 1 Add up to 20 
Cip Control 0 Xng* 0 0 2 1 Add up to 20 
0 0 Xng* 0 2 1 Add up to 20 
Ligase control 0 0 Xng* 0 2 0 Add up to 20 
* For CIP control and Ligase control, the amount of vector DNA was equal to the 
amount of vector DNA used in Experiment 1 and 2. 
 
Ligation was carried out at room temperature for 4 hours. DH5α cells were then 
transformed with 10ul ligation mix as described in section 4.2.4.2 Plasmid DNA was 
prepared from single colonies as described in section 4.2.4.4. 
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4.2.4.11 Preparation of Glycerol Stocks 
 
Stocks of E. Coli cells with the desired recombinant plasmid were prepared as 




A single bacterial colony with the desired plasmid was incubated in 3ml of 2YT 
Broth (with 10mg ampicillin) at 37
o
C overnight. Overnight cultures were aliquotted 
into 1.5ml cryotubes and sterile glycerol was added to the aliquot such that the final 
concentration of glycerol solution was 15%. Aliquots were then clearly labeled, snap-






4.3.1 Extraction of DNA from PEPV and VACV 
 
PEPV and VACV DNA was extracted for PCR amplification of the 2 flanking 
sequences of the PEPV TK gene and the VACV K1L gene respectively as described in 
section 4.2.1. The extracted VACV and PEPV DNA was examined by standard agarose 
gel electrophoresis as shown in Figure 4.6, lanes 2 and 3 respectively. Poxvirus DNA is 
in the order of 200kb. From the result shown the largest molecular weight marker is 
23.13kb and the poxvirus DNA looks to be the same size. This is because standard 
agarose gel electrophoresis limited its ability to resolve fragments of sizes larger than 
20kb. The DNA concentration was measured by NanoDrop
®
, Spectrophotometer ND-
1000. The viral DNA was diluted to 1-5ng/μl for use in PCR reactions (section 4.3.2). 
93 







Figure 4.6. Agarose gel electrophoresis of the DNA extraction products from VACV 
and PEPV. Lane 1 - lambda Hind III DNA molecular weight marker (see Appendix II); 
Lane 2 – VACV DNA; Lane 3 – PEPV DNA 
 
4.3.2 PCR Amplification of VACV K1L and PEPV TK Flanking Sequences 
 
The first step in the transfer vector construction was to amplify VACV K1L and PEPV 
TK fragments by PCR (Figure 4.3A) before the cloning procedure.  
 
PCR amplification was carried out as described in section 4.2.2. A fragment of 
approximately 290bp (Figure 4.7, lanes 3 and 4) was amplified from PEPV genomic 
DNA using the TK left flank primer pair (see Table 4.1); whereas a fragment of 
approximately 200bp (Figure 4.7, lane 6 and 7) was amplified from PEPV genomic 
DNA using the TK right flank primer pair (see Table 4.1). This was as expected, as 










1           2         3        4          5        6         7
 
Figure 4.7. Agarose gel electrophoresis of the PCR products amplified from PEPV 
genomic DNA. Lane 1 – 1kb DNA molecular weight marker (see Appendix II); Lanes 2 
and 5 - negative controls with no DNA used in the PCR procedure; Lanes 3 and 4 are 
duplicate PCR reactions (using 5ng and 1ng of DNA respectively) using TK left primers; 
Lanes 6 and 7 are duplicate PCR reactions (using 5ng and 1ng of DNA respectively) 
using TK right primers. 
 
The PCR product, amplified from VACV genomic DNA using the VACV K1L primer 
pair (see Table 4.1) was approximately 1kb when examined by standard agarose gel 
electrophoresis (Figure 4.8, lane 3). This size matches the expected size of the K1L gene 
as deduced from sequence analysis (1088bp, see Figure 4.5, confirmed by sequencing). 
 













Figure 4.8. Amplification of VACV K1L from VACV genomic DNA, using K1L 
forward and reverse primers. PCR products were subjected to 1% agarose gel 
electrophoresis. Lane 1 – lambda Pst I DNA molecular weight marker (see Appendix II); 
Lane 2 – negative control, no DNA; Lane 3 – amplified VACV K1L DNA 
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All 3 PCR products (VACV K1L, TK left and TK right) were cloned into pGEM T Easy 
vector (see Figure 4.3A), as described in the next section. 
 
4.3.3 Cloning of PCR-Amplified Fragments into pGEM T Easy and gel extraction 
of Required Fragments, TK Left, TK Right and VACV K1L 
 
All three amplified PCR products described in the previous section (section 4.3.2) were 
cloned into the pGEM T Easy vector as described in section 4.2.4.3. For the positive 
control, provided by the PCR cloning kit, there were many white colonies (no blue 
colonies), showing that there had been no vector religation and successful ligation of the 
control DNA insert to the vector. No colonies were seen on the negative control plates; 
this indicated that there was no contamination in the competent cells nor in any other 
stocks such as ligase or vector. A large number of colonies were seen on the test plates. 
However, among these colonies, half of them were blue colonies (no insert) and half of 
them were white colonies (with insert). Several white colonies were picked and plasmid 
DNA isolation (mini) was carried out on these colonies as described in section 4.2.4.4.  
 
For cloning of TK left, the plasmids isolated from white colonies were digested with 
Hind III and Pst I. A fragment of 290bp was present in all 14 plasmid preparation 
(Figure 4.9A). Large-scale DNA isolation (maxi) was applied to one of these clones 
with the TK left flank as described in section 4.2.4.5. From the large-scale DNA 
isolation, 5μg of the amplified plasmid was digested with the restriction enzymes, 
HindaIII and Pst I to cleave the PEPV TK left flank from the pGEM T Easy vector. The 













Figure 4.9A. Standard agarose gel electrophoresis of plasmid DNA digested with 
Hind III and Pst I. Lane 1 - λ Hind III DNA molecular weight marker; Lanes 3 ~ 16 - 
selected clones double digested with Hind III and Pst I. Lane 17 - 1kb DNA molecular 
weight marker. Lane 2 - original pGEM T Easy vector double digested with Hind III 




1      2                       1       2
(A)                              (B)
 
Figure 4.9B. Standard agarose gel electrophoresis showing how TK left fragment 
was gel extracted. pGEM TK left was digested with Hind III+Pst I (lane 2) and the 
290bp fragment was eluted from a 1% agarose gel. Lane 1 - 1kb DNA molecular weight 
marker; DNA was extracted from lanes next to lane 2, which were not stained with 




Preparation of VACV K1L gene and PEPV TK right flank were done in the same way as 
that of TK left. The 200bp PEPV TK right flank was excised from pGEM TKright with 
Sma I and Eco RI. The 1kb VACV K1L fragment was excised from pGEM K1L with 
BssoHII. 
 
Once the VACV K1L fragment, TK left and right fragments were gel purified, it was 
vital to examine whether the extracted DNAs were intact and not contaminated with 
pGEM T Easy vector, as contamination may cause religation of the vector and inhibit 
cloning of these fragments into the transfer vector. Figure 4.9C clearly shows that 
extracted DNA remained intact and was of the correct size and ready for the next 
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Figure.4.9C. Products from gel extraction of the VACV K1L fragment and the 
PEPV TK left and right flanks, subjected to standard agarose gel electrophoresis. 
(A) Lane 1 - 1kb DNA molecular weight marker; Lane 2 - TK left flank (290bp); Lane 3 
- TK right flank (200bp). (B) Lane 1 - λ Hind III DNA molecular weight marker; Lane 2 





4.3.4 Cloning of VACV K1L into pLW51  
 
Figure 4.3B shows a schematic diagram of the next cloning procedure in the 
construction of transfer vector, pNCH-3, where gel-extracted VACV K1L gene was 
cloned into pLW51 plasmid.  
 
The extracted and purified VACV K1L gene was ready to be cloned into the vector 
backbone, but prior to cloning, the vector itself was required to be linearized using 
BssoHII, treated with CIP and purified. These procedures were described in section 
4.2.4.9. Figure 4.9C (B) shows the purified K1L fragment (lane 3) and CIP treated 
pLW51 vector (lane 2). Ligation and transformation were carried out as described in 
section 4.2.4.10. Unlike the PCR cloning experiment, the selective media for this 
experiment only contained ampicillin, as blue-white selection could not be utilized in 
this experiment (pLW51 does not contain a Lac Z gene).  
 
After transformation, colonies were picked and plasmid DNA isolation (small-scale) 
and restriction enzyme digestion were carried out to identify the positive clone 
containing the K1L gene. Due to the use of a single restriction enzyme (Bss HII), one 
could expect several cloning results: A single insert with either forward or reverse 
orientation or double inserts with either forward or reverse orientation. To differentiate 
these different possibilities, restriction enzyme digestion was carried out. Table 4.2 
shows the size fragments expected after single HindoIII and double Hind III + Eco RI 
restriction enzyme digestion for the different possible recombinants. Calculations were 







Table 4.2. Sizes of fragments expected after single and double restriction enzyme 
digests to differentiate between different orientations of the insert. 
Orientation Single (forward) Single (reverse) Double (forward) Double (reverse) 
Enzyme Hind III Hind III+ 
Eco RI 
Hind III Hind III+ 
Eco RI 
Hind III Hind III+ 
Eco RI 




4.5kb 3.1kb 3.9kb 3.7kb 4.5kb 3.1kb 3.9kb 3.7kb 
3.1kb 2.7kb 3.7kb 2.7kb 3.1kb 2.7kb 3.7kb 2.7kb 
 1.8kb  1.2kb 1.1kb 1.8kb 1.1kb 1.2kb 



































Figure 4.10A. Plasmid maps of K1L cloned into pLW51 in different orientation and 
as single and double inserts. a) single insert, forward orientation; b) single insert, 
reverse orientation; c) double insert, both in forward orientation and d) double insert, 
both in reverse orientation. 










Figure.4.10B. Standard agarose gel electrophoresis showing clones containing 
K1L in different orientations and with multiple inserts. Lane 1 – GeneRuler
TM
 
1kb DNA molecular weight marker; Lanes 2, 4, 6, and 8 - Hind III restriction enzyme 
digestion of clones 1-4 respectively; Lanes 3, 5, 7, 9 - Hind III+Eco RI double digests 
of clones 1-4 respectively. 
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Analysis based on Table 4.2 and Fig 4.10, confirmed clone 1 contained a single K1L 
insert, in the forward orientation; Hind III gave fragments of 4.5 and 3.1kb (lane 2) and 
double digestion with Hind III and Eco RI gave fragments of 3.1, 2.7 and 1.8kb (lane 3). 
Clone 2 contained a single K1L fragment, in the reverse orientation; Hind III produced 
fragments of 3.9 and 3.7kb (lane 4) and double digestion with Hind III and Eco RI 
produced fragments of 3.7, 2.7 and 1.2kb (lane 5). Clone 3 contained a double K1L 
insert, both in the forward orientation; Hind III produced fragments of 4.5, 3.1 and 
1.1kb (lane 6) and double digestion with Hind III and Eco RI produced fragments of 3.1, 
2.7, 1.8 and 1.1kb (lane 7). Clone 4 contained a double K1L fragment, both in the 
reverse orientation; Hind III produced fragments of 3.9, 3.7 and 1.1kb (lane 8) and 
double digestion with Hind III and Eco RI produced fragments of 3.7, 2.7, 1.2 and 1.1kb 
(lane 9). 
 
A single K1L insert in either forward or reverse orientation was required for the final 
step in the construction of transfer vector pNCH-3 (Fig 4.3D). Clone 1 was used for 
future cloning. It contains: the host range gene (K1L) which serves as a selective marker 
for recombinant PEPV, a Sma I site for insertion of a future gene of interest, a reporter 
gene, GUS, to indicate the presence of a recombinant virus and a direct repeat sequence 
flanking the K1L and GUS genes.  
 
4.3.5 Cloning PEPV TK Flanks into pUC21  
 
Purified and extracted TK left and right flanks from section 4.3.3 were cloned into 
pUC21 prior to the final transfer vector construction. PEPV TK left flank was first 
cloned into the pUC21 vector to produce pUC21TKleft. The PEPV TK right flank was 
then cloned into the recombinant pUC21/TK left flank plasmid. The cloning procedure 
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was followed as described in section 4.2.4.10. Figure 4.3C shows the cloning strategy 
followed in the construction of pUC21TKl+r.  
 
To confirm the cloning of TK left flank into pUC21, isolated plasmid DNA was 
subjected to double restriction enzyme digestion with Hind III + Pst I, which cleaved 
the TK left flank of 290bp from the recombinant plasmid, thus proving its presence 
(Figure 4.11A). The recombinant plasmid, pUC21 TKleft, was prepared in larger 
quantities as described in section 4.2.4.5.  
 









Figure 4.11A. Standard agarose gel electrophoresis showing the presence of PEPV 
TK left flank cloned into pUC21. Lane 1 – λ Pst I DNA molecular weight marker; 
Lane 2 - pUC21, double digested with Hind III and Pst I; Lanes 3 ~15 - Extracted 
plasmid DNA from 12 different colonies, double digested with Hind III and Pst I; Lane 
16 - 1kb DNA molecular weight marker. 
 
TK right flank was isolated from pGEM TKright on a Sma I+Eco RI fragment and 
cloned into pUC21TKleft. Confirmation of the recombinant plasmid, pUC21TKl+r was 
carried out by restriction enzyme digestion (Figure 4.11B). Restriction enzyme analysis 
was done based on the sequences of the TK gene and pUC21. A Hind III site is present 
102 
in the TK right flank (shown in Figure 4.11B), thus single digestion with Hind III will 
digest pUC21TKleft vector once, producing a linearized plasmid of approximately 3kb 
(Figure 4.11C, lane 4) but digestion of pUC21TKl+r with Hind III will produce  




PEPV TK left flank








Figure.4.11B. Plasmid diagram representing the pUC21TKl+r plasmid, showing 
relevant restriction enzyme siteS for the confirmation of PEPV TK flanks. 









Figure 4.11C. Standard agarose gel electrophoresis showing the presence of both 
PEPV TK left and right flankS in recombinant pUC21 plasmid. Lane 1 – 
GeneRuler
TM 
1kb DNA molecular weight marker; Lane 2 - recombinant pUC21TKleft 
plasmid, double digested with Hind III+Pst I, (producing approximately 300bp 
fragment); Lane 3 - clone 1, double digested with Hind III+Pst I, (producing 2 
fragments of approximately 300bp fragment); Lane 4 - recombinant pUC21TKleft 
plasmid, single digested with Hind III; Lane 5 - clone 1, digested with Hind III, 
(producing appoximately 500bp fragment); Lane 6 - 1kb DNA molecular weight marker. 
 
Hind III (233) 
Pst I (539) 
S a I (598) 
Hind I  (76  




Figure 4.11C confirmed the presence of both TKleft and TKright flanks in pUC21TKl+r 
plasmid, by comparing it with pUC21TKleft (lane 4). After the confirmation of the 
presence of both TK flanks, one could proceed to the final step of the construction of 
the transfer vector. 
 
4.3.6 Construction of pNCH-3 Transfer Vector 
 
The ultimate goal of this project was to construct the transfer vector pNCH-3. All the 
necessary elements for the transfer vector were divided among 2 vector backbones, 
pUC21TKl+r and pLW51K1L. Thus the final step, shown in Figure 4.3D, was to insert 
the fragment from pLW51K1L, containing K1L, GUS, the direct repeats and the Sma I 
site downstream of the pmH5 promoter, between the two TK flanks in pUC21TKl+r. 
 
4.3.6.1 Extraction of K1L-GUS Fragment from Recombinant Plasmid 
pLW51K1L 
 
When pLW51K1L is digested with Cla I+Bam HI, two fragments of 3.9kb and 3.7kb 
are generated (Figure 4.12). The 3.9kb fragment (required fragment) consists of a pair 
of direct repeat sequences, GUS reporter gene, K1L gene and a SmaI site for insertion 
of foreign gene(s) (Figure 4.12). The 3.7kb fragment consists of the remainder of 
pLW51K1L. These two fragments (3.9 and 3.7kb) do not separate easily on an 
agarose gel; hence, for the isolation of the required 3.9kb fragment, after double 
digestion with Cla I + Bam HI, the enzymes were heat inactivated at 65
o
C for 15 
minutes and the DNA was digested with a third enzyme, Eco RI. This was to digest 
the vector fragment and produce 3 fragments in total, a 3.9kb fragment (the original 
desired insert), a 3.2kb fragment (partial backbone) and a 0.5kb fragment (partial 
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Figure 4.12. Diagram of pLW51K1L showing fragments generated by digestion 
with ClaOI + BamoHI + Eco RI. The numbers at the ends of the fragments indicate 
their sizes in bp.  
 
Once the Cla I–Bam HI fragment was extracted, it was important to examine if the 
gel extracted product was intact and pure, i.e. no contamination with the original 
pLW51 vector. The identity of the fragment was confirmed by Bss HII digestion, 
which cleaves the 3.9kb fragment twice into fragments of 2.4kb, 1kb (K1L) and 
500bp (Figure 4.13). 
Cla I+Bam HI +Eco RI 
Eco RI (7627) 
Eco RI ( ) 
Cla I (507) 
B s HII (941) 
Bss HII (2072) 
Sma I (4390) 
Bam HI (4393) 
Bam  (4393) 
Sma I  
Bam HI (4394) 
ss HII ss HII 
Cla I (507) 
Eco RI (0) Cla I (507) 
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Figure 4.13 (lanes 3 and 4) shows Bss HII digested gel extracted products produce 2 
visible fragments of 2.4kb and 1.0kb. The fragment of 500bp was too small to be 
visible on the gel. This indicated the gel extracted product contained the K1L gene as 
predicted.  










Figure.4.13. Standard agarose gel electrophoresis confirming the presence of 
BssaHII sites in the gel extracted Cla I – Bam HI fragment and showing vector 
pUC21TKl+r was ready for the final cloning procedure. Lane 1 – λ Pst I DNA 
molecular weight marker; Lane 2 – CIP treated pUC21TKl+r. Lanes 3 and 4 - gel 
extracted product, digested with Bss HII. 
 
4.3.6.2 Cloning of the Gel Extracted K1L-GUS Fragment into pUC21TKl+r  
 
To prepare the vector for cloning, several steps were required to be done prior to the 
final cloning step (Figure 4.3D). The pUC21TKl+r vector was digested with Sma I 
restriction enzyme and immediately treated with CIP. Figure 4.13 (lane 2) shows 
linearized pUC21TKl+r after digestion with SmaI and CIP-treatment. Sma I created 
blunt-ended sites for insertion of the fragment. The extracted fragment however, 
consisted of sticky-ends (Cla I and Bam HI). Thus the fragment was blunt-ended by 
using T4 DNA polymerase to fill the ends with appropriate dNTPs. The blunt-ended 
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fragment was then ligated to the prepared pUC21TKl+r plasmid. Competent cells 
were transformed with the ligation mix, as described in section 4.2.4.10. Plasmid 
DNA isolation (small-scale) was done on the transformed colonies in search of the 
final recombinant plasmid, pNCH-3. 











Figure 4.14A. Standard agarose gel electrophoresis of plasmid DNA isolated in 
search of pNCH-3. Top and bottom Lanes: Lane 1 – λ Pst I DNA molecular weight 
marker; Lane 2 – undigested pUC21TKl+r vector; Lanes 3-14 undigested plasmid 
DNA isolated from picked colonies. 
 
The pUC21TKl+r vector is 3.2kb. The desired plasmid (pNCH-3) is 7kb. Therefore 
one could see a major difference in migration between the vector (Figure 4.14A, lane 
2) and the recombinant (Figure 4.14A, lane 14, bottom half of gel). This potential 
recombined (labelled I24), was digested with  Bss HII to confirm the presence of the 
insert. 
Figure 4.14B (lane 3) shows the potential clone (I24) produced a 1kb fragment after 
digestion with Bss HII. This confirmed the presence of the insert.  
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Figure 4.14B. Standard agarose gel electrophoresis of the plasmid I24 subjected 
to restriction enzyme digestion with Bss HII. Lane 1 – GeneRuler
TM 
1kb DNA 
molecular weight marker; Lane 2 – I24 undigested; Lane 3 - I24 (from Figure 4.14A, 
bottom lane 14), digested with Bss HII; Lane 4 - GeneRuler
TM 
1kb DNA molecular 
weight marker. 
 
Due to the blunt-ended cloning, the cloned insert could be in one of two orientations. 
Primers were designed for the sequencing of I24, and the plasmid was sent to the 
University of Stellenbosch Sequencing Unit, together with the primers, to be 
sequenced. The sequencing data was assembled using BioEdit (version 7.0.5.2). The 
sequence showed K1L to be closer to the PEPV TK right flank and GUS to be near 
the TK left flank. Figure 4.15 shows a diagram of the transfer vector pNCH-3. 
 
The pNCH-3 DNA sequence is shown in Figure 4.16, coloured sequences indicate the  
PEPV TK flanks, VACV promoters, direct repeats, GUS reporter gene and selective 
marker gene, K1L. Present in this transfer vector is a SmaI site downstream of the 
pmH5 promoter, which is suitable for the cloning of foreign genes such as those 
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Figure 4.15. Plasmid diagram representing the final transfer vector pNCH-3, 
showing all elements present within the vector. 
 
pNCH-3 was tested for its ability to rescue the growth of PEPV in RK-13 cells and 
this is described in the next chapter. At the same time attempts were made to isolate a 
recombinant virus expressing K1L and GUS. This would show that it is possible to 
use the transfer vector pNCH-3 for the future construction of recombinant PEPV 
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Figure 4.16. Sequence of pNCH-3 transfer vector. Brown coloured sequences 
indicate the PEPV TK flanking sequences (PEPV TK left and right); green coloured 
sequences indicate the poxvirus promoters (pmH5, PsynII and P11); light blue coloured 
sequences indicate the direct repeats; the dark blue coloured sequence indicates the 
GUS reporter gene; the red coloured sequences indicate the VACV K1L gene; and the 




Transfer vectors are used widely in the construction of recombinant poxviruses (Elahi et 
al., 1999; Dvoracek et al., 2003; Hahn et al., 2000; Perkus et al., 1989). This is the first 
attempt to construct a transfer vector for the generation of a recombinant PEPV. As has 
been previously used (Kit, 1985; Hahn et al., 2000; Perkus et al., 1989), the thymidine 
kinase (TK) gene was chosen as the site of insertion. This gene is not essential for the 
growth of poxviruses in vitro (see section 4.1); therefore it is the gene of choice for 



















recombination is not lethal for growth of the virus in vitro. The TK gene is also located 
in a conserved region of the genome, which would suggest that any recombinant virus 
containing gene(s) inserted in this locus would be stable. 
 
The PEPV thymidine kinase gene was first identified by Daria Kow (1992), by primer 
hybridization. However, the first sequencing work of the TK gene was only done during 
my Honours study (Hu, 2007). During this study, TK sequences of Fowlpox virus and 
Canarypox virus were aligned and primers were designed from the conserved sequences. 
The primers were used to amplify 330 bp of the PEPV TK gene. However, this 
sequence is relatively short to be used as flanking sequences in a transfer vector and the 
probability of homologous recombination taking place would be small (Yao et al., 2001). 
In 2008, most of the PEPV genome was sequenced by Olivia Carulei, Division of 
Medical Virology, Department of Clinical Laboratory Sciences, UCT. The complete 
sequence of PEPV TK (552 bp) was obtained, and used in this study for the construction 
of a PEPV transfer vector. The combined total of the homologous sequence used in this 
study is 496bp (290bp TK left flank and 206bp TK right flank). Yao’s group has shown 
the ideal sequence length for homologous recombination to occur is 366bp in VACV. 
Although Yao’s study was based on VACV, one can apply it to PEPV, therefore it is 
likely for homologous recombination to occur between the transfer vector constructed in 
this study and the PEPV genome.  
 
Stannard et al, used a plasmid containing a reporter gene, LacZ, under the control of the 
VACV P11 promoter. (Stannard et al., 1998). In her study no expression was seen from 
the reporter gene after transient expression of the plasmid in PEPV infected RK-13 cells, 
indicating no transcriptase was present to modulate the late promoter and hence initiate 
the transcription of the reporter gene (Stannard et al., 1998). In this study, the P11 
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promoter was used to express the reporter gene, GUS. If GUS is expressed, then the 
presence of K1L would have rescued late gene expression and it could be possible to 
rescue recombinant PEPV in RK-13 cells using VACV K1L.  
 
The next chapter describes the rescue of PEPV growth in RK-13 cells using VACV-K1L. 
If this were to be successful then the next step would be to clone an antigen gene(s) of 
interest into the Sma I site of pNCH-3 (Figure 4.15). Once the entire gene cassette is 
inserted into the PEPV genome, producing blue plaques in RK-13 cells, one could then 
passage the virus on chick CAMs in order to remove the K1L and GUS genes by means 
of spontaneous deletion of the sequence between the 2 direct repeats. The final PEPV 
recombinant would have only the gene of interest inserted into the TK locus. This 
desired recombinant could be identified by PCR of individual picked pocks.  
114 
Chapter 5: Rescue of PEPV Growth in RK-13 Cells and Attempts to Construct 
Recombinant PEPV 
 
5.1 Introduction 115 
 
5.2 Materials and Methods 116 
5.2.1 Infection and Transfection of RK-13 Cells 116 
5.2.2 Detection of GUS Reporter Gene Expression using X-gluc  
.as a Substrate 117 
5.2.3 Preparation of Cell Extracts for PCR 118 
5.2.4 PCR Amplification 118 
 
5.3 Results 119 
      5.3.1 Evidence to Show Growth of PEPV was Rescued by 
               VACV K1L Gene Expression 119 
      5.3.2 Attempts to Construct a Recombinant PEPV which  
               Expresses GUS and K1L 121 
      5.3.3 PCR Amplification of DNA from the Cell Lysate of 
               Infected RK-13 Cells 121 
 




The first VACV host range genes were discovered when researchers attempted to 
generate temperature sensitive VACV mutants. During the screening of mutagenized 
viral stock, VACV host range mutants were discovered. These mutants were found to 
exhibit altered plaque morphology on permissive cell-lines or showed restricted growth 
in previously permissive cell-lines (Drillien et al., 1981). K1L was the first host range 
gene to be discovered. K1L knockout VACV was shown to grow in human cells; 
however, it showed restricted growth in rabbit kidney (RK-13) cells (Perkus et al., 
1990). Later, Sutter showed expression of VACV K1L in RK-13 cells complemented the 
host range defect of VACV mutants (Sutter et al., 1994). This again was shown when 
the growth of highly attenuated Modified Vaccinia Ankara, (derived from VACV that 
was passaged >500 times in primary chick embryo fibroblast (CEF) cells, and which 
had lost its ability to replicate in RK-13 cells), was rescued by VACV K1L expression 
(Wyatt et al., 1998). 
 
It is not known whether the K1L gene product alone can rescue Avipoxvirus growth in 
RK-13 cells. It is an early gene product which is required for translation to take place 
following poxvirus infection of cells. VACV K1L has been shown to bind host PKR (see 
section 3.1.2), and so is expected to block phosphorylation of elF2 by PKR 
phosphorylation. In this study, the transfer vector, pNCH-3, was designed in such a way 
that the promoters expressing both the reporter gene (GUS) and the K1L gene were 
poxvirus promoters. Poxvirus promoters only function in the presence of Poxvirus 
transcription factors. Hence expression of the reporter gene would show that both 
infection and transfection have taken place. Replication and formation of plaques would 
then show that K1L has rescued late gene expression. 
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5.2 Materials and Methods 
 
5.2.1 Infection and Transfection of RK-13 Cells 
 
Infection and transfection was performed to determine whether PEPV would recognize 
the VACV promoters, and whether VACV K1L expression could rescue growth of 
PEPV in RK-13 cells. 
 
RK-13 cells were prepared as described in section 3.2.1. Fresh RK-13 cells were seeded 
into sterile 6-well plates. Once the wells were 50% - 70% confluent, plates were 
infected with PEPV as described in section 3.2.2.1 and transfected with transfer vector 
pNCH-3. 
 
Transfection was carried out as described in the manufacturer’s instruction of a 
tranfection kit, Effectene (supplied by QIAGEN). This kit contained Effectene, a 
nonliposomal lipid reagent and an enhancer which condenses DNA. The condensed 
DNA mixed with Effectene forms small transfection complexes which enables the 
plasmid DNA to be transported into the cells by fusion through the cell membrane. 
 
For transfection of cells in one well of a 6-well tissue culture plate; 0.4-1μg of plasmid 
DNA was diluted with buffer EC to a final volume of 100μl, followed by addition of 
3.2μl Enhancer. Reagents were mixed thoroughly by vortexing prior to incubation at 
room temperature for 2-5 minutes. Ten microlitre of Effectene reagent was added after 
the incubation; the contents were mixed gently, but thoroughly by pipetting up and 
down gently. The transfection mix was then incubated at room temperature for 5-10 
minutes prior to the addition of 600μl DMEM, with PS, fungin and 2%FCS. This mix 
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was added drop wise to the cell surface; this was followed by the addition of 1.6ml 
DMEM with PS, fungin and 2%FCS to each well. Plates were then incubated at 37
o
C 
with 5% CO2 for 2-5 day. PEPV was harvested from cells as described in section 3.2.2.2. 
 
5.2.2 Detection of GUS Reporter Gene Expression using X-gluc as a Substrate 
 
The reporter gene, β-glucuronidase (GUS), was included in the transfer vector, 
primarily to aid in the isolation of recombinant virus containing this gene. It also allows 
one to monitor the efficiency of transfection of infected cells. GUS enzyme is capable 
of digesting the substrate X-gluc and turning the RK-13 cells blue. 
 
A stock of 20mg/ml X-gluc was prepared, wrapped in foil paper and stored at -20
o
C. X-
gluc was first diluted to 0.2mg/ml in DMEM with P/S, fungin and 2%FCS. All the 
medium in the wells was removed and the wells were rinsed with 1xPBS before adding 
0.5ml of diluted X-gluc solution to each well. 
 
For agarose overlays, melted agarose was added to the medium containing X-gluc to a 
final concentration of 1% agarose and 0.5ml of melted agarose overlay was added to 
each well swiftly after the 1xPBS wash. Working quickly was important to prevent 
agarose from polymerizing before adding it to the well. The plates were first kept at 
room temperature for the agarose to polymerize before incubating at 37
o







5.2.3 Preparation of Cell Extracts for PCR  
 
For detection of recombinant virus, DNA was extracted from the infected and 
transfected cells and subjected to PCR analysis. Wells were gently washed with 1xPBS 
prior to cell lysis. First, 100μl of lysis buffer A (100mM KCl, 10mM Tris-HCl of pH 8.3 
and 2.5mM MgCl2) was added to each well. The plates were incubated at room 
temperature for 5 minutes. Secondly, 100μl of lysis buffer B (10mM Tris-HCl of pH 8.3, 
2.5mM MgCl2, 1% Tween 20, 1% NP40 and 120μg/ml Proteinase K) was added to each 
well. The contents of the well were pipetted into 1.5ml microfuge tubes and incubated at 
60
o
C for 1hr to allow Proteinase K to perform its function of protein degradation. Lastly, 
the tubes were incubated at 95
o
C for 10 minutes to inactivate the Proteinase K. DNA 




C in 1.5ml microfuge tubes and used as template in the 
subsequent PCR experiments. 
 
5.2.4 PCR Amplification 
 
PCR was performed as described in section 4.2.2 to determine whether recombination 
had taken place or not. The K1L reverse primer together with a primer which binds to 
PEPV DNA downstream of the TK gene (DTK right, 5’ 











5.3.1 Evidence to Show Growth of PEPV was Rescued by VACV K1L Gene 
Expression 
 
RK-13 cells were initially infected with 3 known different virus concentrations and 
transfected with 600ng of pNCH-3, as described in sections 5.2.1. The experiment was 
performed in a 6-well sterile tissue culture plate as shown in Table 5.1 and Figure 5.1. 
Infected and/or transfected cells were stained with X-gluc (substrate for GUS reporter 
gene) 48 hours post infection as described in section 5.2.2. Photographs were taken 
using an inverted microscope 24 hours post staining.  
 
All 3 negative controls showed no CPE characteristic of viral infection (Figure 5.1A-C) 
nor blue cells. This indicated that pNCH-3 vector alone could not produce GUS protein 
and PEPV alone could not produce infectious progeny in RK-13 cells. In all 3 
experiments where both PEPV and VACV K1L were present noticeable CPE and/or 
plaques were visible (Figure 5.1D-F). Severe infection was seen at the highest PEPV 
concentration of an MOI of one infectious virus particle per cell (Figure 5.1 D).  
 
This experiment, in particular the large blue plaque seen in Figure 5.1F suggests that 









Table 5.1. Contents of individual wells used to examine whether transfection 
of pNCH-3 can rescue the growth of PEPV in RK-13 cells* 
Well 1 - Cells Only (A) 
- Negative control 
- No infection 
- No transfection 
Well 2 - pNCH-3 Only** (B) 
- Negative control 
- No infection 
- Transfection with 600ng 
pNCH-3 
Well 3 - PEPV Only*** (C) 
- Negative control 
- Infect with MOI of 0.1 
- No transfection 
Well 4 - PEPV / pNCH-3 (D) 
- Experiment 
- Infect with MOI of 1 
- Transfection with 600ng 
pNCH-3 
Well 5 - PEPV / pNCH-3 (E) 
- Experiment 
- Infect with MOI of 0.1 
- Transfection with 600ng 
pNCH-3 
Well 6 - PEPV / pNCH-3 (F) 
- Experiment 
- Infect with MOI of 0.01 
- Transfection with 600ng 
pNCH-3 
*Images of individual wells are shown below in Figure 5.1. 
**Examine if pNCH-3 alone can produce GUS protein. 
*** Examine if infection with PEPV alone can produce viral plaques. 
 
  
(A)Well - 1                           (B) Well - 2                           (C) Well - 3 
 
(D) Well - 4                           (E) Well - 5                            (F) Well - 6 
Figure 5.1. X-gluc stained RK-13 cells visualized using an inverted microscope at 
40X magnification, 3 days post infection. A) Well 1 - Cells only; B) Well 2 - 
Transfection with 600ng pNCH-3 only; C) Well 3 - Infection with PEPV at an MOI of 
0.1; D-F) Infection with PEPV at an MOI of 1, 0.1 and 0.01 respectively followed by 





5.3.2 Attempts to Construct a Recombinant PEPV Which Expresses GUS 
 
The purpose of the construction of the transfer vector pNCH-3 was to engineer a 
recombinant PEPV. Therefore the next step of this experiment was to search for a 
recombinant PEPV expressing K1L and GUS.  
 
RK-13 cells were infected and transfected as described in section 5.2.1, harvested as 
described in section 3.2.2.2 and the cell lysate passaged in RK-13 cells. Plaques were 
seen after 3 days of the first passage, and used to infect RK-13 cells again. On the 
second passage, no blue plaues were seen, but CPE was seen after 5-7 days. It was 
unclear whether this was due to the presence of virus or simply cell death. When stained 
for GUS expression, no blue coloration was observed. PEPV is unlikely to adapt to 
growth in RK-13 cells, as shown in Chapter 3. Moreover it was not known whether the 
plaques seen after the first passage were due to the presence of recombinant virus which 
did not grow upon further passage; or whether they resulted from cells both infected 
with PEPV and transfected with plasmid pNCH-3. This was further investigated by PCR 
analysis of the cell lysates of infected and/or transfected RK-13 cells (see section 5.3.3). 
 
5.3.3 PCR Amplification on the Cell Lysate of Infected RK-13 Cells 
 
PCR was performed in order to determine whether any recombinant PEPV was 
generated after infection and transfection as described in section 5.2.1. A 6-well plate of 
RK-13 cells was infected and/or transfected as depicted in the grid below, the same 





Table 5.2. Contents of individual wells used to examine for the presence of 
recombinant PEPV 
Well 1 - Cells Only 
- Negative control 
- No infection 
- No transfection 
Well 2 - pNCH-3 Only 
- Negative control 
- No infection 
- Transfection with 600ng 
pNCH-3 
Well 3 - PEPV Only 
- Negative control 
- Infect with MOI of 0.1 
- No transfection 
Well 4 - PEPV / pNCH-3 
- Experiment 
- Infect with MOI of 1 
- Transfection with 600ng 
pNCH-3 
Well 5 - PEPV / pNCH-3 
- Experiment 
- Infect with MOI of 0.1 
- Transfection with 600ng 
pNCH-3 
Well 6 - PEPV / pNCH-3 
- Experiment 
- Infect with MOI of 0.01 
- Transfection with 600ng 
pNCH-3 
 
After infection and transfection had taken place, the plate was incubated at 37
o
C, 5% 
CO2 for 2-5 days prior to cell lysis. Cells were lysed as described in section 5.2.3. 
Isolated DNA was subjected to PCR as described in sections 4.2.2 and 5.2.4, using 
selected primers shown in Tablea5.3. Table 5.3 shows all possible outcomes of the PCR 
amplification of DNA from the infected cell lysates. PCR products were subjected to 
standard agarose gel electrophoresis, which is shown in Figure 5.2. 
 
Table 5.3. Primer pairs used for PCR amplification of DNA from cell lysates 
depicted in Table 5.2 and expected sizes of DNA products  
 Primer pair 1 Primer pair 2 Primer pair 3 
 (K1L forward + 
K1L reverse) 
(UTK left* +  
DTK right**) 
(DTK right** + 
 K1L reverse) 
Function 
Identify K1L 
fragment (plasmid or 
recombinant PEPV) 
Identify non-
disrupted TK gene 
(wt PEPV) 
Identify TK disrupted 
by K1L (recombinant 
PEPV) 
Forward Primer K1L forward UTK left* DTK right** 
Reverse Primer K1L reverse DTK right** K1L reverse 
No DNA No DNA fragment No DNA fragment No DNA fragment 
Cells only (well1) No DNA fragment No DNA fragment No DNA fragment 
pNCH-3 only (well 2) 1 kb fragment No DNA fragment No DNA fragment 
PEPV only (well 3) No DNA fragment 1 kb fragment No DNA fragment 
Possible recombinant 
PEPV (wells 4~6) 
1 kb fragment 5kb fragment  
(too large for 
amplification) 
2.5kb fragment 
*Sequence in PEPV that was situated upstream of TK gene  
(5’ GGAAATAGCTAGAGAAACGCTAA 3’) 
**Sequence in PEPV that was situated downstream of TK gene  
(5’ TGTATCTTACAAACTGAATTTCAG 3’) 
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In Table 5.3, primer pair 1 was used to detect K1L (Figure 5.2, lanes 2, 5, 8, 11 and 14), 
primer pair 2 was used to detect wt PEPV TK (Figure 5.2, lanes 3, 6, 9, 12 and 15) and 
primer pair 3 was used to detect recombinant virus (Fiure 5.2, lanes 4, 7, 10, 13 and 16). 
Both the positive controls with appropriate sizes can be seen in Figure 5.2. Lane 8 
shows the K1L fragment amplified from pNCH-3 and lane 12 shows the TK fragment 
amplified from the wtPEPV genome. However no DNA was amplified from primer pair 
3, which was specific for recombinant PEPV (Figure 5.2, lane 16) . Lanes 14 and 15 
show the presence of pNCH-3 and wtPEPV respectively in the infected and transfected 
cells.  
 






PEPV only PEPV and
Plasmid
 
Figure 5.2. Standard agarose gel electrophoresis showing PCR amplified products 
from cell lysates depicted in Tables 5.2 and 5.3. Lane 1 - 1kb DNA molecular weight 
marker; Lanes 2-4 - negative control for PCR experiment, using H2O in place of 
template DNA; Lanes 5-7- cells only; Lanes 8~10 – pNCH-3 transfected cells; Lanes 
11-13 – PEPV infected cells; Lane 14~16 – PEPV-infected and pNCH-3 transfected 
cells. Primer pair 1 (K1L) was used in lanes 2, 5, 8, 11 and 14; Primer pair 2 (PEPV TK) 
was used in lanes 3, 6, 9, 12 and 15; Primer pair 3 (PEPV TK+K1L) was used in lanes 4, 
7, 10, 13 and 16. 
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This result suggests that the CPE generated in the cells both infected with PEPV and 
transfected with pNCH-3 was attributed to transient expression of K1L in cells infected 
with PEPV and transfected with pNCH-3. However, it is possible that, in addition to 
transient expression, a small amount of recombinant virus was formed but not detected 
in the PCR assay due to the relatively large size of the fragment to be amplified (2.5kb) 
and the somewhat fuzzy bands detected from amplification of viral DNA (Figure 5.2, 
lanes 12 and 15). The extention time of 4 minutes should have been sufficient to 
amplify a fragment of 2.5kb. Primers were designed to amplify a fragment of 2.5kb, and 
not smaller, as it was important that the one primer bind outside of the TK flanking 
sequence present in the plasmid. The insensitivity of the assay may be due to the 
presence of PCR inhibitors in the lysates. Sensitivity assays were not performed to test 
the detection level. This could have been done by spiking the uninfected cell lysate with 
known amounts of PEPV DNA and determining the number of genomes required to 




The VACV K1L gene was used to rescue the growth of PEPV in RK-13 cells, in order 
to isolate recombinant PEPV in RK-13 cells. During the growth rescue experiment, RK-
13 cells were infected with wtPEPV and transfected with the pNCH-3 plasmid. Plaques 
and CPE were observed in the infected and transfected cells, and after staining with X-
Gluc, blue cells were seen surrounding the plaques as shown in section 5.3.1, Figure 5.1. 
This suggested that expression of K1L was able to rescue the growth of PEPV in RK-13 
cells. However, when the “rescued” virus was passaged in fresh RK-13 cells, plaques 
and CPE were seen in the first passage but not thereafter. PCR analysis was carried out 
for detection of the recombinant virus and was unable to detect the presence of 
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recombinant virus (see section 5.3.3). It is possible that recombinant virus is generated 
at a level too low for detection by PCR following infection and transfection, but needs 
to be amplified by passage before being detectable. 
 
To explain the inability of recombinant virus to grow upon passage, one has to examine 
at which stage the blockage in replication of PEPV in RK-13 cells occurs. In the 
previous work done by Stannard et al (1998), no sign of infection or CPE was identified 
in PEPV infected RK-13 cells. Poxvirus early proteins are responsible for the rounding 
of host cells, however severe CPE was not observed in the PEPV infected RK13 cells. 
This may suggest that, after viral entry, viral protein incorporated within the virus 
package, somehow only transcribes certain early genes, and there is probably no 
translation (with no K1L equivalent). Hence, severe CPE does not take place and virus 
alone was unable to progress to the intermediate phase of the replication cycle, thus 
replication was abolished. During the rescue experiment, CPE was seen after infection 
with PEPV and transfection with pNCH-3 plasmid. Thus it indicated that K1L was 
capable of producing the necessary viral early proteins for the virus to progress to a late 
stage of the replication cycle. The X-gluc staining experiment showed that GUS was 
expressed. The GUS gene was regulated by a Poxvirus late promoter, P11, indicating 
that replication of PEPV DNA must have take place, as well as translation of the 
intermediate proteins, which regulate late gene expression. However, it is not known 
why rescued PEPV was unable to be passaged. 
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Chapter 6: Conclusion 
 
This thesis describes preliminary groundwork performed in the development of PEPV 
as a vaccine vector. With no cells known to be permissive for PEPV growth, the virus 
was grown and titrated on the CAMs of 10-12 day old chick embryos. It was confirmed 
by growth curves that PEPV cannot multiply in RK-13 cells and does not adapt to 
growth in these cells upon multiple passage.  
 
In a series of cloning experiments, a transfer vector pNCH-3 was constructed which 
consists of the selective host range gene, K1L and marker gene, GUS, flanked by direct 
repeat sequences, outside of which is a unique Sma I restriction enzyme site for future 
cloning experiments, and all of these elements are flanked by PEPV TK sequences. This 
transfer vector, pNCH-3, containing VACV K1L, was shown to rescue PEPV growth in 
RK-13 cells. Although infected and transfected cells appeared blue and plaques 
surrounded by blue cells were visible, no recombinant virus could be recovered after 
passage of these cell lysate.  
 
This is the first attempt to complement PEPV in a non-permissive cell line with a host 
range gene to restore virus growth. The results obtained are inconclusive as to whether 
K1L can be used as gene for selection of recombinant virus, but do provide a foundation 
for future work on the construction of recombinant PEPV. Even if the K1L host range 
gene is not employed in the future, the vector pUC21TKl+r containing the PEPV TK 
flanking sequences could be used to test other positive selection genes such as gpt, if a 
cell line permissive to PEPV growth is found.  
 
For future work, one could compare the sequence of PEPV with other poxviruses that 
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are known to grow in RK-13 cells, and search for the possible host range gene that will 
enable PEPV to complete its replication cycle in RK-13 cells. This study showed K1L 
was able to rescue early and late gene expression, thus to limit the area of investigation, 
one could search for late genes that are associated with host range. However, due to 
time constraints, further investigation into host restriction was not done. 
 
At present PEPV has been unable to complete its replication cycle in any of the tested 
cell-lines, including CEFs. This unusual nature (most Avipoxviruses grow in CEF cells) 
may indicate that PEPV may be a particularly safe vector to use for a vaccine as PEPV 
is more restrained compared to other known Avipoxviruses. However, to construct a 
recombinant virus, one is required to grow the PEPV in a permissive cell line; therefore 
further research still needs to be conducted in the search for a cell-line permissive to the 





Appendix I: Vector Diagrams 
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